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Abstract 
Leukaemia is a family of haematological malignancies and is responsible for 
approximately 4500 deaths in the UK annually. Despite extensive research and 
development within this disease area over the last decade, there has been little 
change in the overall survival, risk of relapse and side effects, highlighting the need 
for improved chemotherapeutics. 
Lignans are polyphenolic compounds found naturally in plants and have been 
suggested to have antioxidant properties and inhibitory effects on the Wnt/ß-catenin 
and the PI3K/Akt cell signalling pathways which are aberrantly activated in leukaemia. 
A series of eighteen novel compounds have been synthesised based on a natural 
lignan extract, each with structural modifications to the side chains of each molecule. 
The effects of the eighteen lignan derivatives on the leukaemia cell line Jurkat were 
investigated. Biochemical activity as an indirect measure of viability was assessed 
using the MTS assay, while apoptosis and necrosis were investigated using the 
Annexin V/Propidium Iodide assay. Cell cycle analysis by DNA quantification was also 
performed to determine any arrest in cycle induced by the compounds. Additionally, 
Western Blotting analysis was performed on lignan treated cell lysates to identify 
changes in protein expression that would suggest effects on the Wnt/ß-catenin and 
the PI3K/Akt signalling pathways. HSPB1 and HSPA1A expression was analysed to 
determine the cellular stress response. 
Data indicate that the lignan compounds SD007, SD013 and SD018 significantly 
affect cellular metabolism and induce apoptosis following treatment. Cell cycle 
analysis demonstrates there is a significant reduction in Jurkat cells entering G2-
phase, which further indicates the pro-apoptotic effect of the lignan compounds. 
Western Blotting analysis suggests there is a cellular stress response induced by 
lignan compound treatment, due to the increased expression of the stress protein 
HSPB1. However, no change in phosphorylated levels of ß-catenin or Akt were 
observed, suggesting that these particular lignan compounds have no effect on the 
Wnt/ß-catenin or the PI3K/Akt pathways. 
Further study is necessary to establish the cell signalling cascades affected by lignan 
compound treatment, however the data obtained highlight lignan compounds SD007, 
SD013 and SD018 for further development and refinement as anti-leukaemia agents.  
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1.0 Introduction 
 
1.1 Background to leukaemia and treatments 
Leukaemia is the collective term for a family of haematological malignancies that are 
characterised by the aberrant proliferation of immature leukocytes initially in the bone 
marrow. There are in excess of 9000 cases of leukaemia diagnosed each year in the 
UK, with approximately 4500 deaths attributed to the disease annually (Neal and 
Hoskin, 2012). It is also the most abundant form of paediatric cancer (ages 0-14), 
accounting for 30% of cancer diagnoses, 78% of which can be classified as Acute 
Lymphoblastic Leukaemia (ALL; Cancer Research UK, 2017). The 5-year survival rate 
for patients with ALL is 70%, however this varies depending on factors such as age, 
subtype, cytogenetic aberrations and responsiveness to treatment. (Cancer 
Research UK, 2017). 
Broadly, the subclassification of leukaemia is determined by categorising the disease 
onset as either acute or chronic, and the malignant cell as belonging to either the 
myeloid or lymphoid cell lineage (Neal and Hoskin, 2012). Specifically, acute T-cell 
lymphoblastic leukaemia (T-ALL) is a malignancy which occurs during the 
lymphoblast stage of haematopoiesis (Figure 1.1.1), which affects the clonal 
production of T-lymphocytes. T-ALL accounts for between 15-20% of ALL 
diagnoses and is associated with a poor prognostic outcome (Hoelzer and 
Gökbuget, 2009).  
Deregulated proliferation of the immature lymphoblasts within the bone marrow 
suppresses the production of erythrocytes, thrombocytes and leukocytes (Neal and 
Hoskin, 2012). This failure of the bone marrow instigates the typical symptoms of 
leukaemia, which includes anaemia, frequent and unexplained bleeding, and 
susceptibility to infections. Additionally, swelling of the liver, spleen and lymph nodes 
can occur due to extramedullary haematopoiesis in these organs following bone 
marrow failure (Kim, 2010). 
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Figure 1.1.1: Haematopoietic stem cell tree, highlighting the lymphoid lineage 
adapted from Cancer Research UK. 
 
Chromosomal abnormalities or gene mutations within the haematopoietic stem cell 
are an established characteristic of leukaemia, frequent examples of which include 
mutations affecting tumour protein 53 (TP53) and Notch Homolog 1, translocation 
associated (Drosophilia; NOTCH1), transcription factor rearrangements, and the 
presence of the Philadelphia chromosome (Zuckerman and Rowe, 2014). While 
these chromosomal aberrations may be pathogenetically significant, in T-ALL these 
are not reason for subclassification due to varying biological features among patients 
(Vardiman et al., 2009). The prognosis and treatment options can vary depending on 
the karyotype of the patient, with some chromosomal abnormalities responding 
positively with targeted therapies (An et al., 2010). An example of this is using 
dasatinib or imatinib as specific agents in Philadelphia chromosome positive T-ALL 
patients. 
Typically, treatment for ALL comprises anti-cancer chemotherapy, and is received in 
three stages – induction, consolidation and maintenance (Neal and Hoskin, 2012). 
Options for induction chemotherapy include varying combinations of daunorubicin, 
vincristine, prednisone, asparaginase and occasionally cyclophosphamide (Bailey, 
1992; Joel and Rohatiner, 2002). Use of these drugs is accompanied by a wide range 
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of side effects due to the non-specific nature of the drug for the T-ALL cell. Once the 
patient has achieved remission, consolidation treatment will be started to prevent re-
emergence of the leukaemic clone. Drugs used in this phase include cytarabine (Ara-
C), etoposide, methotrexate and 6-mercaptopurine, all of which are also targeting 
any rapidly dividing cells. Maintenance therapy consists of lower dose chemotherapy 
with the same drugs for approximately 18-24 months to achieve long-term remission. 
Due to the non-specific nature of anti-cancer chemotherapy, debilitating side effects 
of the treatment such as fatigue, nausea and a weakened immune system are 
common. Additionally, despite achieving a remission, some patients can become 
refractory to the drugs used during treatment. Patients with Philadelphia 
chromosome positive chronic myeloid leukaemia (CML) may become resistant to 
imatinib mesylate, which would require an alternative tyrosine kinase inhibitor or 
other treatment to be sought (Bitencourt et al., 2011). 
Side effects, along with acquired and inherited resistance to the aging chemotherapy 
arsenal, makes continued research into newer targeted agents for the disease a 
necessity (Alfarouk et al., 2015; Neal and Hoskin, 2012). Current clinical trials such 
as the UKALL 14 which focuses on adults with ALL, and UKALL2011 which focuses 
on patients aged 1-24 years, have been designed to improve our understanding of 
how modifications to the current protocols can both sustain disease remission and 
minimise side effects  (Vora, 2012; Neal and Hoskin, 2012). 
 
1.2 Cytotoxicity and Cellular Stress 
 
1.2.1 Cell Death Machinery – Apoptosis and necrosis 
Cell death is a natural physiological process that occurs in the life of all organisms, 
and can be distinguished by two alternative modes, apoptosis and necrosis 
(Adamczyk et al., 1998).  
Apoptosis, which is also known as programmed cell death, is a vital part of normal 
cell turnover and development. Approximately ten billion cells are apoptosed daily in 
order to maintain cell number homeostasis (Renehan et al., 2001). Evasion of 
apoptosis is one of the six hallmarks of cancer (Hanahan and Weinberg, 2011), which 
in some patients with chronic lymphocytic leukaemia (CLL) for example, could be 
attributed to a combined over-expression of the bcl2 oncogene and dysregulation of 
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the tumour suppressor gene p53 (Otake et al., 2007). Morphologically, apoptosis is 
characterised by cell shrinkage and chromatin condensation, events that follow the 
early translocation of phosphatidylserine (PS) from the inner to the outer leaflet of the 
plasma membrane (Elmore, 2007). Cysteine-aspartic proteases (caspases) are 
enzymes essential to the apoptotic process, that are activated by either the extrinsic 
(death receptor) or the intrinsic (mitochondrial) apoptotic signalling pathways (Ichim 
et al., 2016). Both pathways converge at the same point to form the execution phase 
(Elmore, 2007). 
The extrinsic pathway (Figure 1.2.1) is activated by the binding of a ligand to the 
corresponding death receptor, such as tumour necrosis factor (TNF)-related 
apoptosis-inducing ligand receptor 1 (TRAILR1) or first apoptosis signal (FAS) 
receptor (Ichim et al., 2016). Fas-associated protein with death domain (FADD), an 
adapter protein, heterodimerises pro-caspase-8 and pro-caspase-10, which 
activates the initiators caspase-8 and caspase-10. The execution pathway begins, 
where caspase-8 cleaves and activates caspase-3 and caspase-7. Caspase-3 
inactivation of the flippase ATPase Phospholipid Transporting 11C (ATP11C) and  
activation of scramblase XK-related protein 8 (Xkr8) is one of the mechanisms 
responsible for the externalisation of PS, which facilitates phagocytosis of the 
apoptotic cell by macrophages (Segawa and Nagata, 2015).  
The intrinsic pathway (Figure 1.2.2) is a mitochondria-based apoptosis mechanism, 
which is initiated by a variety of lethal stimuli including DNA damage, hypoxia and 
metabolic stress (Ichim et al., 2016). These stimuli lead to the activation of pro-
apoptotic effectors Bax and Bak, which results in mitochondrial outer membrane 
permeabilisation (MOMP) and the ensuing release of the pro-apoptotic protein 
cytochrome c into the cytosol (Brentnall et al., 2013). Cytochrome c associates with 
apoptotic protease activating factor 1 (Apaf-1) to form the apoptosome, which 
activates caspase-9. Caspase-9 cleaves and activates caspase-3 and caspase-7,  
and as with the extrinsic pathway, the execution phase continues (Elmore, 2007). 
Cross talk between the extrinsic and intrinsic pathways occur through caspase-8 
cleavage of the BH3-only protein Bid, generating the active truncated form of Bid 
(tBid) (Brentnall et al., 2013). tBid also activates Bax and Bak, thus resulting in MOMP 
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and cytochrome c release, serving to further amplify the apoptotic process (Ichim et 
al., 2016).  
The anti-apoptotic protein Bcl-2 exists to block the further activation of Bax, Bak and 
Bid, which prevents MOMP from occurring (Ichim et al., 2016). In normal cells, Bcl-
2 is essential for development and sustaining cellular homeostasis, however, as 
previously mentioned, deregulation of Bcl-2 expression in malignancy can contribute 
to the prevention of apoptosis in cancer cells (Otake et al., 2007).  
 
 
Figure 1.2.1: Extrinsic apoptosis pathway adapted from Elmore et al. 2007 
 
 
Figure 1.2.2: Intrinsic apoptosis pathway adapted from Elmore et al. 2007 
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Necrosis can be differentiated from apoptosis by changes in cell morphology (Figure 
1.2.3), which includes swelling of the cell and its organelles, production of reactive 
oxygen species (ROS) and irreversible loss of plasma membrane integrity 
(Matsumura et al., 2000). Necrosis can occur as a result of a number of cellular 
stresses, including hypoxia, complement attack, and toxin exposure (Matsumura et 
al., 2000). Ligands belonging to the tumour necrosis factor (TNF) family are known 
initiators of both apoptosis and necrosis, the outcome of which is determined by 
both the type of cell and the particular context (Festjens et al., 2006). For example, 
Fas binding in the absence or deficiency of FADD will not lead to caspase-8 
activation and therefore the extrinsic apoptotic pathway cannot proceed, so the cell 
will induce necrosis (Festjens et al., 2006).  
 
Figure 1.2.3: Differences in cell morphology during the processes of necrosis 
(left) and apoptosis (right) - adapted from Ichim et al. 2016. 
 
Despite the reputation of necrosis as being an unorganised process, relatively recent 
literature has suggested that necrosis is another form of programmed cell death 
(Vanden Berghe et al., 2013; Edinger and Thompson, 2004). However, necrosis 
differs from apoptosis by the activation of a local inflammatory response, which is 
triggered by the release of cytokines from the necrotic cell (Golstein and Kroemer, 
2007). The inflammatory response can be beneficial to the host by alerting the 
immune system to cell death and initiating tissue repair, however inflammation can 
elicit damage of host tissues by ROS and proteases, which serve to enhance the 
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pathogenesis of the underlying disease and exacerbate the condition of the host 
(Rock and Kono, 2008).  
 
 
1.2.2 Heat Shock Proteins and Cellular Stress 
Heat Shock Proteins (HSPs) are a group of molecular chaperones that under normal 
conditions, facilitate and sustain protein folding, as well as assist with protein 
trafficking (Kaul and Thippeswamy, 2011). A number of HSPs are upregulated during 
stressful conditions to prevent protein unfolding and inhibit cell death pathways, and 
once the stress stimulus passes, the levels of HSPs return to a baseline level 
(Dempsey-Hibbert et al., 2012). Transcription is regulated by transcription factors 
from the heat shock factor (HSF) family, which ensures swift activation and 
subsequent deactivation following recovery from the stressful stimuli (Ciocca and 
Calderwood, 2005). 
HSPs were previously categorised into families based on the molecular weights of 
the proteins themselves. However, following the discovery of more HSPs and the 
sequencing of the human genome, HSP nomenclature was reviewed and the 
proteins were renamed after the genes responsible for their synthesis (Kampinga et 
al., 2009). 
A wealth of studies have documented the role of HSPs in human cancers (Ciocca 
and Calderwood, 2005), especially the contribution of HSPB1, HSPA1A and HSPC1 
(previously known as Hsp27, Hsp72 and Hsp90, respectively).  
 
HSPB1 and HSPA1A have been associated with conferring anti-apoptotic properties 
to cancer cells where they are over-expressed (Dempsey-Hibbert et al., 2012). The 
transfection of a plasmid containing HSPB1 into testicular cancer cells conferred 
resistance to the chemotherapeutic agents cisplatin and doxorubicin (Richards et al., 
1996). HSPA1A has been shown to inhibit the formation of the apoptosome by 
directly targeting Apaf-1 (Kuwana et al., 2000). However conflicting data do exist, 
and HSPA1A has also been associated with increased Fas-mediated apoptosis in 
leukaemic T-cells (Creagh et al., 2000).  
  8 
Increased levels of HSPs in leukaemia patients have been correlated with a poor 
prognosis (Dempsey-Hibbert et al., 2012). This is not universal in all cancers, as 
HSPA1A expression in osteosarcoma is associated with higher sensitivity to 
treatment, but HSPB1 expression is still associated with a poor prognosis (Ciocca 
and Calderwood, 2005). However, as observed in CLL, over-expression of one HSP 
does not suggest that levels of other HSPs may be elevated simultaneously 
(Dempsey et al., 2010).  
Previous literature has suggested that existing elevated levels of several families of 
HSPs are associated with chemotherapy resistance in some cancers. For example, 
elevated levels of HSPB1 has been associated with cisplatin resistance in cervical 
cancer (Zhu et al., 2016). Furthermore, a cytotoxic agent can induce the expression 
of several HSPs from baseline levels, which itself can confer resistance against the 
agent. Attention has been drawn to the combined use of HSP inhibitors and 
chemotherapeutic agents, with the aim of preventing drug-induced HSP expression 
and consequent drug resistance (Sulthana et al., 2017; Li et al., 2009). HSPC1 (also 
known as Hsp90) inhibitors, such as AUY922 and 17-DMAG in particular, have 
shown moderate success in Phase I and Phase II clinical trials, and more recently 
HSPB1 has been targeted using an anti-sense inhibitor known as apatorsen (OGX-
427) (Oki et al., 2015; Mellatyar et al., 2016; Chi et al., 2016). It is important to 
understand the effects of any prospective new drug compound on the heat shock 
response to be able to foresee the potential for resistance to the compound. 
 
1.3 Cell Signalling 
 
1.3.1 Wnt/β-Catenin Pathway 
The canonical Wnt/β-Catenin pathway (Figure 1.3.1.1) is an evolutionarily conserved 
cell-signalling cascade that is essential from the earliest stages of mammalian 
embryonic development in virtually all tissues and continues throughout the life of an 
organism (Kahn, 2014). There are nineteen different Wnt ligands within the Wnt 
family, and ten receptors for the ligands to associate, which lends to the overall 
complexity of the cascade (Lento et al., 2013). 
The pathway is responsible for regulating proliferation and development of the 
haematopoietic stem cell (HSC), ensuring the balance between self-renewal and 
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differentiation is maintained (Ashihara et al., 2015). The signalling cascade is active 
in the developing T-cell until single positive selection in the thymus, at which point 
the levels of the Wnt ligand are negligible (Gopal et al., 2014). In haematological 
malignancy, the pathway is aberrantly activated, which contributes to the 
characteristic uncontrolled proliferation of immature blast cells (Ashihara et al., 
2015).  
β-catenin is a multifunctional protein found in a number of subcellular compartments 
and is essential in the formation of the cytoskeleton. In the pathways “off” state, the 
β-catenin destruction complex, which consists of adenomatous polyposis coli (APC), 
the scaffold protein Axin, glycogen synthase kinase 3-β (GSK3β) and casein kinase 
1α (CK1), ubiquitinates β-catenin which targets the protein for degradation by the 
proteasome (Ashihara et al., 2015). However, in the “on” state, the Wnt ligand binds 
to frizzled (Fz) and its co-receptor lipoprotein receptor-related protein 5/6 (LRP5/6). 
This leads to the binding of Dishevelled (Dvl) with Fz, which interrupts the formation 
of the β-catenin destruction complex, which in turn allows β-catenin to escape 
degradation and accumulate in the cytoplasm (Ashihara et al., 2015; Bafico et al., 
2004; MacDonald et al., 2009). The β-catenin enters the nucleus and binds to 
lymphoid enhancer factor/T-cell factor (LEF/TCF), which allows transcription of 
target genes such as cyclin D1 and c-myc and drives cell proliferation (Pećina-Šlaus, 
2010). 
The role of the pathway in proliferation has highlighted the opportunity for 
therapeutic intervention. Over the past few years, pathway inhibitors have been 
developed and entered Phase I clinical trials with some success (Lu et al., 2016). 
However, due to the role of the Wnt/β-catenin pathway in normal homeostasis and 
other pathway interactions, it is important that novel anti-cancer targeted treatments 
do not affect the regular tissue development and repair (Kahn, 2014; Zhang and Hao, 
2015). 
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Figure 1.3.1: The canonical Wnt/β-catenin pathway as occurs in both the 
presence and absence of Wnt – adapted from Ashihara et al. 2015. 
 
1.3.2 PI3K/Akt Pathway 
The PI3K/Akt pathway is a complex cell signalling cascade involving many 
components that promotes cell survival and growth and is also important in the 
regulation of the cell cycle (Fekete et al., 2012). 
Binding of extracellular factors to receptor tyrosine kinases (RTK) phosphorylates the 
receptor and leads to the recruitment and activation of phosphoinositide-3-kinase 
(PI3K). The activated PI3K phosphorylates intracellular membrane-bound 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-
trisphosphate (PIP3), which leads to the recruitment and activation of the proto-onco 
protein Akt (also known as PKB) (Nicholson and Anderson, 2002). In addition to other 
subcellular functions which remain to be elucidated, Akt is able to suppress MOMP 
by phosphorylating pro-apoptotic Bad and thus promoting cell survival (Song et al., 
2005). 
Literature has suggested that the PI3K/Akt pathway can accelerate cell cycle 
progression, a potential mechanism of which is the over-expression of cyclin D1 as 
a result of upregulation by Akt (Nicholson and Anderson, 2002; Chang et al., 2003). 
  11 
Targeted therapies affecting the PI3K/Akt pathway have been developed, such as 
KRX-0401 and GSK263677. and are undergoing Phase I and Phase II clinical trials 
with varying degrees of success in colorectal cancer patients (Bahrami et al., 2017). 
 
1.4 Lignans 
Lignans are a family of diphenolic plant compounds, which are particularly abundant 
in flax and sesame seeds (Ramos, 2008). They are also present in some fruits, 
vegetables and grains, albeit at a lower concentration (Peterson et al., 2010). The 
basic chemical structure of a lignan consists of two C6C3 units (propylbenzene; 
Figure 1.4.1), which are linked by a carbon-carbon bond at position 8,8’ (Moss, 
2000). Previous literature has indicated that natural lignans possess anti-cancer, 
anti-oxidant, and anti-inflammatory properties (Saleem et al., 2005; Peterson et al., 
2010), which has led to a heightened interest in their pharmacological potential.  
 
 
Figure 1.4.1: Chemical structure of a lignan, coupled at the 8,8’ position - 
adapted from Moss, 2000. 
 
 
The metabolism of plant lignans by intestinal bacteria produces the mammalian 
lignans enterodiol and enterolactone, the latter of which has also been identified as 
a useful biomarker for measuring dietary lignan exposure (Kuijsten et al., 2005).  
Enterodiol and enterolactone possess oestrogen-like biological properties and can 
therefore bind to the type II oestrogen receptor in place of oestradiol. Depending on 
the dose and cancer cell line, this can induce either oestrogenic or antioestrogenic 
responses (Wang, 2002). This is promising for further research in the treatment of 
hormone-sensitive cancers, such as those of the breast and prostate. 
The cytotoxic and cytostatic properties of lignan-based compounds have been 
previously described in the literature. The lignan podophyllotoxin is too cytotoxic to 
  12 
be considered for cancer treatment, however its semi-synthetic derivatives, 
etoposide and teniposide, are included in treatment protocols for some cancers, 
including leukaemia and lymphoma (Gordaliza et al., 2000). Etoposide and 
teniposide, which are cytostatic agents, cause breaks in DNA by inhibiting 
topoisomerase IIa, which subsequently arrests the cancer cells in G2/M phase. 
Despite repair of the DNA breaks, affected cells lose their clonogenicity  (Schonn et 
al., 2010). As teniposide is more readily absorbed by cells, accumulation within the 
cells can result in cytotoxicity (Long, 1992). 
Viability assays determined that leukaemia and melanoma cell lines were more 
sensitive to treatment with the natural lignan (-)-sesamin, than brain and ovarian 
cancer cell lines (Saeed et al., 2014). The same study also compared the IC50 values 
of (-)-sesamin with those of other lignans and derivatives, including arctigenin, 
podophyllotoxin, teniposide and etoposide. This comparison demonstrated that 
despite (-)-sesamin and arctigenin being less cytotoxic than podophyllotoxin, 
etoposide and teniposide, they are still promising candidates for further cancer drug 
development (Saeed et al., 2014). 
Adding to data showing cytostatic properties of lignans, studies have also shown 
that lignans possess pro-apoptotic properties. The naturally-derived lignan 
arctigenin upregulated the expression of the pro-apoptotic gene Bad in a T-cell 
lymphoma cell line (Su et al., 2015), and apoptosis was also observed following 
treatment of colon carcinoma cells with arctigenin (Hausott et al., 2003). Another 
study showed that expression of the pro-apoptotic protein Bax was upregulated and 
the expression of anti-apoptotic Bcl-2 was downregulated in fourteen different 
cancer cell lines following treatment with the novel synthetic lignan Vitexin 6 (Zhou 
et al., 2013). 
A previous study showed that the treatment of a colon cancer cell line (SW480) with 
three different lignans reduced the levels of β-catenin, with arctigenin showing the 
most significant effect (Yoo et al., 2010). Additionally, a previous study demonstrated 
that treatment of a prostate cancer cell line (LNCaP) with the lignan matairesinol, 
decreased Akt activity which had previously been implicated as responsible for the 
resistance LNCaP cells to TRAIL-induced apoptosis (Peuhu et al., 2010).  
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Our collaborators in the School of Chemical Sciences at the University of Auckland, 
New Zealand, synthesised a bank of eighteen lignan derivatives. These were 
produced by structural modifications of the original butyrolactone extract, the 
purpose of which was to have a direct effect on the efficacy of the compound. The 
eighteen lignan compounds are indicated in Table 1.4.1. No previous anti-cancer 
research has been performed using this particular group of eighteen novel lignan 
compounds, emphasising the novelty of this particular study. 
 
 
 
 
Table 1.4.1: Code, chemical structure, and molecular weights of each lignan 
derivative. 
Code Chemical Structure Molecular Weight (kDa) 
   
SD001 
 
416.4642 
SD002 
 
446.4902 
SD003 
 
400.4218 
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SD004 
 
402.4376 
SD005 
 
400.4218 
SD006 
 
430.4530 
SD007 
 
384.3840 
SD008 
 
386.4440 
SD009 
 
416.4642 
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SD010 
 
370.4010 
SD011 
 
386.4600 
SD012 
 
370.4010 
SD013 
 
354.3580 
SD014 
 
356.3740 
SD015 
 
372.4170 
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SD016 
 
400.4270 
SD017 
 
386.4000 
SD018 
[(-)-
SD013] 
 
354.3580 
 
 
 
1.5 Aims and Objectives 
It is clear from the previous literature that some members of the lignan family have 
anti-cancer properties and some seem to show greater efficacy than others. 
However, their mode of action and effects on the cellular stress response remain to 
be determined. The aim of the project was to identify the potential of the synthetic 
lignans as anti-leukaemia agents. This was achieved by accomplishing the following 
objectives: 
1. To determine the cytotoxic/cytostatic effects of a new set of novel lignan 
compounds on the Jurkat T-cell leukaemia cell line. 
2. To elucidate the signalling pathways affected by the compounds. 
3. To establish the degree of cellular stress caused by the compounds by 
analysis of HSP expression. 
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2.0 Materials and Methods 
2.1 Materials 
2.1.1 Consumables 
0.2 mL PCR Tubes 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
I1402-8100 
  
0.5 mL Microcentrifuge Tubes 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1605-0000 
  
1.5 mL Microcentrifuge Tubes 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1615-5500 
  
1000 µL XL Graduated Filter Tip 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1122-1730-C 
  
10 µL Graduated Filter Tip 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1121-2710-C 
  
1250 µL XL Graduated Tip 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1112-1720-C 
  
2.0 mL Microcentrifuge Tubes 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1620-2700 
  
200 µL UltraPoint Graduated Tip 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1113-1700-C 
  
200 µL Graduated Filter Tip 
Starlab UK Ltd. 
Milton Keynes, Buckinghamshire, UK 
Product 
S1120-8710-C 
  
Bijoux Container Tubes (7 mL) 
Scientific Laboratory Supplies Ltd. 
Nottingham, Nottinghamshire, UK 
Product 
SLS7522 
  
Centrifuge Tube 15 mL 
Sarstedt Ltd. 
Leicester, Leicestershire, UK 
Product 
62.554.502 
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Centrifuge Tube 50 mL 
Sarstedt Ltd. 
Leicester, Leicestershire, UK 
Product 
62.547.254 
  
Falcon® 5 mL Polystyrene Round Bottomed Tubes 
Corning Ltd. 
Deeside, Flintshire, UK 
Product 
352052 
  
Nunc™ 25 cm2 Cell Culture Flasks 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
156367 
  
Nunc™ Microwell™ 12 Well Microplates 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
150628 
  
Nunc™ Microwell™ 24 Well Microplates 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
142475 
  
Nunc™ Microwell™ 48 Well Microplates 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
150687 
  
Nunc™ Microwell™ 96 Well Microplates 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
167008 
  
Serological Pipette 10 mL 
Sarstedt Ltd. 
Leicester, Leicestershire, UK 
Product 
86.1254.001 
  
Serological Pipette 25 mL 
Sarstedt Ltd. 
Leicester, Leicestershire, UK 
Product 
86.1685.001 
  
Serological Pipette 5 mL 
Sarstedt Ltd. 
Leicester, Leicestershire, UK 
Product 
86.1253.001 
  
Universal Container Tubes (30 mL) 
Scientific Laboratory Supplies Ltd. 
Nottingham, Nottinghamshire, UK 
Product 
SLS7500 
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2.1.2 Reagents 
10X Annexin V Binding Buffer 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
556454 
  
30% Acrylamide/Bis 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
161-0158 
  
(S)-(+)-Camptothecin 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
C9911 
  
Akt Antibody 
Cell Signalling Technology, Inc. 
Leiden, The Netherlands 
Product 
9272S 
  
Ammonium Persulphate 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
A3678 
  
Annexin V-FITC 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
556419 
  
Anti-Rabbit IgG, HRP-linked Antibody 
Cell Signalling Technology, Inc. 
Leiden, The Netherlands 
Product 
7074S 
  
β-Actin (13E5) Rabbit mAb 
Cell Signalling Technology, Inc. 
Leiden, The Netherlands 
Product 
4970S 
  
Bovine Serum Albumin Fraction V 
Roche Products Ltd. 
Welwyn, Hertfordshire, UK 
Product 
10735086001 
  
CellTiter 96® AQueous One Solution Cell Proliferation Assay 
Promega UK 
Southampton, Hampshire, UK 
Product 
G3580 
 
CS&T Research Beads 
BD Biosciences 
Oxford, Oxfordshire, UK 
 
Product 
650621 
  
Dimethyl Sulphoxide (DMSO) 
Fisher Bioreagents UK Ltd. 
Loughborough, Leicestershire, UK 
Product 
BP231 
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Dulbecco’s Phosphate-Buffered Saline 
Lonza Biologics Plc 
Slough, Berkshire, UK 
Product 
BE17-512F 
  
Ethanol, Absolute (200 Proof) 
Fisher Scientific UK Ltd. 
Loughborough, Leicestershire, UK 
CAS 
64-17-5 
  
FACSclean 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
340345 
  
FACSflow 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
342003 
  
Foetal Bovine Serum (Gibco) 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
10270-106 
  
Glycine 
Fisher Scientific UK Ltd 
Loughborough, Leicestershire, UK 
Product 
BP381-1 
  
Goat Anti-Mouse IgG (HRP Conjugate) 
Enzo Life Sciences (UK) Ltd. 
Exeter, Devon, UK 
Product 
BML-SA204 
  
Hsp27 Monoclonal Antibody (G3.1) 
Enzo Life Sciences (UK) Ltd. 
Exeter, Devon, UK 
Product 
ADI-SPA-800D 
  
Hsp72 Monoclonal Antibody (C92F3A-5) 
Enzo Life Sciences 
Exeter, Devon, UK 
Product 
ADI-SPA-810D 
  
iScript™ cDNA Synthesis Kit 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
170-8891 
  
Jurkat, Clone E6.1  
LGC Standards S.a.r.l. 
Teddington, Middlesex, UK 
Product 
ATCC TIB-152 
  
N, N, N’, N’-Tetramethylethylenediamine (TEMED) 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
161-0800 
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NuPage™ LDS Sample Buffer (4X) 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
NP007 
  
Phosphatase Inhibitor Cocktail II 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
P5726 
  
Phospho-Akt (Ser473) Antibody 
Cell Signalling Technology, Inc. 
Leiden, The Netherlands 
Product 
9271S 
  
Phospho-β-Catenin (Ser45) Antibody 
Cell Signalling Technology, Inc. 
Leiden, The Netherlands 
Product 
9564S 
  
Pierce™ BCA Protein Assay Kit 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
23227 
  
Pierce™ ECL Western Blotting Substrate 
Thermo Fisher Scientific 
Loughborough, Leicestershire, UK 
Product 
32209 
  
Precision Plus Protein™ Dual Colour Standards 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
161-0374 
  
Propidium Iodide 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
P4170 
 
Protease Inhibitor Cocktail 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
 
Product 
P8340 
  
RNase A 
Roche Products Ltd. 
Welwyn, Hertfordshire, UK 
Product 
10109142001 
  
RPMI 1640 Media 
Lonza Biologics Plc 
Slough, Berkshire, UK 
Product 
BE12-115F 
  
Sodium Chloride 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
S3014 
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Sodium Deoxycholate 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
S1827 
  
Sodium Dodecyl Sulphate 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
L3771 
  
Trans-Blot® Turbo™ RTA Mini Nitrocellulose Transfer Kit 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
170-4270 
  
Tris Base 
Fisher Scientific UK Ltd 
Loughborough, Leicestershire, UK 
Product 
BP152-1 
  
Triton X-100 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
T8787 
  
Trypan Blue Solution 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
T8154 
  
Tween® 20 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Product 
93773 
 
 
2.1.3 Equipment 
Centrifuge 
Sigma-Aldrich Company Ltd. 
Gillingham, Dorset, UK 
Model 
3-16-PK 
  
ChemiDoc™ Touch Imaging System 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Model 
1700-1401 
  
Class II Safety Cabinet 
Labcaire Systems Ltd. 
Southend-on-Sea, Essex, UK 
Model 
S18R-UV 
  
CO2 Incubator 
Nuaire Ltd. 
Doncaster, South Yorkshire, UK 
Model 
NU5500E 
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FACSCalibur™ Flow Cytometer 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
342973 
  
FACSVerse™ Flow Cytometer 
BD Biosciences 
Oxford, Oxfordshire, UK 
Product 
651154 
  
Haemocytometer 
VWR International Ltd. 
Lutterworth, Leicestershire, UK 
Product 
8110204 
  
Microplate Reader 
Bio-Tek® Instruments Ltd. 
Swindon, Wiltshire, UK 
Model 
Synergy HT 
  
Microscope 
Nikon Corporation Ltd. 
Kingston-upon-Thames, Surrey, UK 
Model 
TMS-F-301547 
 
Mini Protean® Tetra Cell, 1.0 mm Plates, Stand, Clamps 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
 
Product 
165-8003FC 
  
PowerPac™ Basic Power Supply 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
164-5050 
  
Trans-Blot® Turbo™ Transfer System 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Product 
170-4155 
 
 
2.1.4 Software 
CellQuest Pro 
BD Biosciences 
Oxford, Oxfordshire, UK 
Version 
3.1.1 
  
FACSuite 
BD Biosciences 
Oxford, Oxfordshire, UK 
Version 
21.0.1 
  
Gen 5 Data Analysis 
Bio-Tek® Instruments Ltd. 
Swindon, Wiltshire, UK 
Version 
2.0.1 
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GraphPad PRISM® 
GraphPad Software Inc. 
La Jolla, California, USA 
Version 
5.0a 
  
Imagelab 
Bio-Rad Laboratories Ltd. 
Watford, Hertfordshire, UK 
Version 
5.2.1 
  
Microsoft Excel 2013 
Microsoft Ltd. 
Reading, Berkshire, UK 
Version 
15.0.4 
  
ModFit LT 
Verity House Software 
Topsham, Maine, USA 
Version 
5.0.9 
  
 
2.1.5 Buffers and Solutions 
 
1.0 M Tris-HCl 6.8 100 mL 
Tris Base 12.1 g 
dH2O 100 mL 
Adjust to pH 6.8  
  
1.5 M Tris-HCl 8.8 100 mL 
Tris Base 12.1 g 
dH2O 100 mL 
Adjust to pH 8.8  
  
1:1000 Primary Antibody 3 mL 
2.5% BSA in TBS-Tween 3 mL 
Antibody required  3 µL 
  
1:5000 Secondary Antibody 20 mL 
2.5% BSA in TBS-Tween 20 mL 
Antibody Required 4 µL 
  
10% Ammonium Persulphate 1 mL 
Ammonium Persulphate 0.1 g 
dH2O 1 mL 
  
10% Sodium Dodecyl Sulphate 100 mL 
Sodium Dodecyl Sulphate 10 g 
dH2O 100 mL 
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10X Tris Buffered Saline (TBS) 1 L 
Tris Base 24 g 
Sodium Chloride 88 g 
dH2O 1 L 
Adjust pH to 7.6  
To make 1X – add 100 mL 10X TBS to 900 mL dH2O  
  
1000X Propidium Iodide (PI) 500 µL 
Propidium Iodide 25 mg 
DPBS 500 µL 
To make 1X – add 20 µL to 19.98 mL DPBS  
  
10X Running Buffer 1 L 
Tris Base 30.3 g 
Glycine 142.6 g 
Sodium Dodecyl Sulphate 10 g 
dH2O 1 L 
To make 1X – add 100 mL 10X Running Buffer to 900 mL dH2O  
 
2.5% BSA in TBS-Tween 
 
20 mL 
BSA Fraction V 0.5 g 
TBS-Tween 20 mL 
  
20X RNase-A 12.5 mL 
RNase-A 25 mg 
dH2O 12.5 mL 
To make 1X – add 500µL 20X RNase-A to 10mL dH2O  
  
5% BSA in TBS-Tween 20 mL 
BSA Fraction V 1.0 g 
TBS-Tween 20 mL 
  
Resolving Gel (10%) 15 mL 
dH2O   5.9 mL 
30% Bis Acrylamide 5 mL 
1.5 M Tris 8.8 3.8 mL 
10% SDS 150 µL 
10% APS 150 µL 
TEMED 6 µL 
  
Resolving Gel (8%) 15 mL 
dH2O   6.9 mL 
30% Bis Acrylamide 3.9 mL 
1.5 M Tris 8.8 3.8 mL 
10% SDS 150 µL 
10% APS 150 µL 
TEMED 8 µL 
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RIPA Buffer 100 mL 
Tris Base 0.61 g 
Sodium Chloride 0.29 g 
Sodium Deoxycholate 0.5 g 
Sodium Dodecyl Sulphate 0.1 g 
Triton X-100 1 mL 
dH2O   99 mL 
Adjust to pH 7.4  
  
Stacking Gel (4%) 6 mL 
dH2O   4.1 mL 
30% Bis Acrylamide 1.0 mL 
1.0 M Tris 6.8 750 µL 
10% SDS 60 µL 
10% APS 60 µL 
TEMED 6 µL 
  
TBS with Tween® 20 (TBS-Tween) 1 L 
1X TBS 999 mL 
Tween® 20 1 mL 
 
 
 
2.2 Methods 
2.2.1 Compound Reconstitution and Preparation 
The lignan compounds were transported in a lyophilized state from the University of 
Auckland, New Zealand and were a kind gift from Dr. David Barker. Depending on 
the mass of the compound, they were diluted to concentrations of 5-12 mg/mL using 
100% dimethyl sulfoxide (DMSO; Thermo Fisher Scientific, UK) as the vehicle. Each 
compound was vortexed for 5 seconds and placed in a sonicating waterbath for 5 
minutes at room temperature. The compounds were then stored at room 
temperature. 
When preparing solutions from stock, the reconstituted lignan compound was 
diluted in required volumes of RPMI 1640 media (Lonza, UK) supplemented with 
10% foetal bovine serum (FBS; Thermo Fisher Scientific, UK). Serial dilutions were 
performed from this solution to obtain any other desired concentrations. All lignan 
compound solutions were prepared at 2X concentration and were therefore diluted 
to 1X concentration when incubated with the cell suspension at a 1:1 ratio.  
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2.2.2 Cell Culture 
Jurkat E6.1 cells were cultured in RPMI 1640 media supplemented with 10% FBS 
(herein referred to as 10% RPMI) in vented T25 flasks. Cells were incubated at 37 °C 
in a 5% CO2 humidified environment and were routinely sub-cultured upon reaching 
a density of between 2.0-2.5x106 cells/mL. 
Before treatment with the compounds, cell viability was assessed using the trypan 
blue exclusion method. For this, a 100 µL aliquot was taken from the flask and placed 
in a 0.5 mL microcentrifuge tube and mixed with 100 µL 0.4% trypan blue solution 
(Sigma, UK). The cell and trypan blue mixture was placed in a haemocytometer and 
counted under the microscope, with the average number of cells used to calculate 
the cell density within 1 mL of culture. Trypan blue is excluded from viable cells by 
the intact cell membrane, while non-viable cells absorb the stain and appear blue 
under the microscope. Experiments were only performed when cell viability was 
more than 95% within the given culture of Jurkat cells.  
The volume of culture media containing the correct number of cells required for the 
entire experiment was removed from the suspension and placed in a 15mL centrifuge 
tube and spun in a centrifuge at 500 x g for 5 minutes at room temperature. Following 
centrifugation, the supernatant was removed, and the cell pellet was resuspended in 
fresh 10% RPMI at the required density before seeding the cells into culture plates. 
 
2.2.3 MTS Assay 
The CellTiter 96® AQueousOne Solution Cell Proliferation Assay (Promega, UK) is a 
colorimetric method used to determine the number of viable cells in cytotoxicity and 
proliferation assays. The solution contains the novel tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS), which is reduced by metabolically active cells to form 
a soluble formazan product. This product is directly proportional to the number of 
viable cells in culture (Promega Corporation, 2012). 
A suspension of Jurkat cells was prepared as per Section 2.2.2, and aliquoted into a 
96 well flat-bottomed plate (100 µL; 2.0x105 cells/well). Five concentrations of each 
lignan compound were prepared as described in Section 2.2.1, and 100 µL of each 
concentration was added to the appropriate cell suspensions at final concentrations 
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of either 200 µM, 100 µM, 50 µM, 25 µM or 12.5 µM per well. Untreated and non-
viable controls were also prepared by treating the cell suspension with 100 µL of 
10% RPMI and absolute ethanol, respectively. All treatments were performed in 
triplicate, except the untreated controls which had six replicates. The plate 
containing the cells was incubated at 37 °C in a 5% CO2 humidified incubator for 
either 24 hours, or 48 hours. 
Following incubation, the contents of each well were placed in 0.5 mL 
microcentrifuge tubes and centrifuged at 500 x g for 5 minutes at room temperature. 
The supernatant was removed, and the pellet was displaced with 100 µL of fresh 
10% RPMI. The mixtures were replaced into a 96 well flat-bottomed plate, with 20 
µL of CellTiter 96® AQueousOne Solution Cell Proliferation Assay added to each well. 
The plate was protected from the light with foil and incubated at 37 °C in a 5% CO2 
humidified environment for 2.5 hours. The plate was analysed using a Synergy HT 
plate reader (BioTek, UK) which measured the absorbance of the solutions at 450 
nm.  
 
2.2.4 Annexin V/Propidium Iodide Assay 
The Annexin V/PI assay is a bivariate flow cytometric assay which is used to 
distinguish the mode of cell death within a sample. Annexin V, a Ca2+-dependent 
protein that has high affinity for the membrane protein PS, is conjugated with a FITC 
fluorochrome, which can be used to analyse apoptosis with flow cytometry. This is 
performed in conjunction with propidium iodide (PI), a dye that intercalates with DNA. 
During necrosis and the later stages of apoptosis, the plasma membrane becomes 
permeable to PI, therefore the nucleus of these cells will fluoresce red (Vermes et al., 
2000). Photons are emitted following excitation by the laser and are detected by 
photomultiplying tubes, and by measuring the presence or absence of Annexin V 
and PI, can be categorized as viable, early apoptotic, late apoptotic or necrotic (Table 
2.2.4.1). 
A suspension of Jurkat cells was prepared as described in Section 2.2.2, and 
aliquoted into a 96 well flat-bottomed plate (100 µL; 1.0x105 cells/well). Three 
concentrations of each lignan compound were prepared as per Section 2.2.1, and 
100 µL of each concentration was added to the appropriate cell suspensions at final 
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concentrations of either 200 µM, 100 µM or 50 µM per well. Each concentration of 
lignan compound was incubated with the Jurkat cells in triplicate. Untreated controls 
were also performed using 100 µL of 10% RPMI media, in place of the lignan 
compound solutions. The plate containing the cells was incubated at 37 °C in a 5% 
CO2 humidified incubator for 24 hours. 
The cells were removed from the wells and placed in 1.5 mL microcentrifuge tubes 
and were spun in a centrifuge at 500 x g for 5 minutes at room temperature. The 
supernatant was removed, and the pellet was resuspended in 300 µL of Dulbecco’s 
Phosphate Buffered Saline (DPBS; Lonza, UK) and centrifuged again at 500 x g for 
5 minutes at room temperature. The supernatant was removed, and the pellet was 
resuspended in 100 µL of 1X Annexin V Binding Buffer (BD Biosciences, UK), then 
transferred to a capped 5mL polystyrene round bottomed tube (Corning, UK). A 15 
µL aliquot from master mix containing 2:1 Propidium Iodide to Annexin V-FITC (both 
BD Biosciences, UK) was added to each tube, mixed, and incubated in the dark for 
15 minutes at room temperature. An additional 400 µL of 1X Annexin V Binding Buffer 
was added to the tubes, and the contents were immediately analysed using a BD 
FACSVerse™ flow cytometer and FACSuite™ analysis software (both BD 
Biosciences, UK). 
Initially, the Jurkat cell population was identified and gated using forward scatter 
(FSC) and side scatter (SSC) of a sample with no fluorochromes present (unstained). 
This gate was applied to each sample that was tested (Figure 2.2.4.1). 
Once identified, the population was gated in order to discard the debris, and the 
voltages of the photomultiplier tubes were adjusted to remove background 
fluorescence of FITC and PI. Compensation controls containing single stains of either 
Annexin V-FITC or PI were then analysed to calculate and adjust for spectral overlap. 
The experimental samples were then analysed and were grouped according to the 
results as shown in Table 2.2.4.1.  
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Figure 2.2.4.1: Dotplot of events following flow cytometric acquisition of an 
untreated control sample. Gate “P1” selects the Jurkat cell population based on Side 
Scatter (SSC) and Forward Scatter (FSC), which was applied to each sample analysed. 
 
 
Table 2.2.4.1: Viability of cells according to measured fluorescence. 
 
 
 
 
 
 
2.2.5 Cell Cycle Analysis 
The stages of cell cycle progression can be categorised by measuring DNA content 
within cells using the DNA-intercalating agent PI, which can be quantified using a 
flow cytometer. The cells can be categorised as either G1, S, or G2/M phase with a 
DNA content of 2n, >2n and 4n, respectively (Figure 2.2.5.1) (Nicoletti et al., 1991; 
Riccardi and Nicoletti, 2006). 
A suspension of Jurkat cells as prepared as described in Section 2.2.2, and aliquoted 
into a 48 well flat-bottomed plate (200 µL; 1.2x106 cells/well). The lignan compounds 
were prepared as per Section 2.2.1, and 200 µL of each concentration was added to 
the appropriate cell suspensions at a final concentration of 100 µM per well. 
Untreated controls were also performed, incubating the Jurkat cells with 200 µL of 
 Annexin V-FITC Propidium Iodide 
Viable - - 
Early Apoptotic + - 
Late Apoptotic + + 
Necrotic - + 
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10% RPMI instead of lignan compound. Additionally, positive controls were 
performed, using 0.5 µM camptothecin to induce cell cycle arrest. 
 
 
 
 
 
 
 
 
 
Figure 2.2.5.1: Diagram indicating cell cycle progression through interphase and 
the mitotic phase – adapted from Williams and Stoeber, 2011. 
 
All treatments and controls were performed in triplicate. The plate containing the 
cells was then incubated at 37 °C in a 5% CO2 humidified incubator for 4 hours. 
Shorter incubations were chosen for cell cycle analysis to observe the initial stages 
of lignan compound exposure to the Jurkat cells. 
Following incubation, the cells were removed from the plate and replaced in 1.5 mL 
microcentrifuge tubes. The samples were spun in a centrifuge at 500 x g for 5 
minutes at room temperature, and once completed the supernatant from the 
samples were discarded, leaving the pellet. The pellet was vortexed while 
simultaneously adding 500 µL 70% ethanol dropwise, fixing the cells and minimising 
clumping. The samples were incubated at 4 °C for 30 minutes, and then centrifuged 
at 1000 x g for 5 minutes. The supernatant was discarded, and the pellet was 
resuspended in 500 µL DPBS. The samples were spun again at 1000 x g for 5 
minutes, and the supernatant was removed a final time. The pellet was resuspended 
in 50µL RNase A (100 µg/mL stock; Roche, UK) and 200 µL PI (50 µg/mL stock; 
Sigma, UK). The samples were then analysed using a BD FACScalibur™ flow 
cytometer with BD CellQuest™ Pro analysis software (both BD Biosciences, UK). 
The Jurkat cell population was detected by measuring the FSC/SSC of the sample, 
and gating the cells, which excluded the majority of debris from further analysis. 
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Within this population, another gate was constructed using FL2-A/FL2-W that 
included cells twice the area which characterised mitosis but excluded cells twice 
the width which would indicate cell clumping (Figure 2.2.5.1). 
The data produced following analysis of the samples was then processed using 
ModFit LT™ v5.0.9 (Verity House Software, USA), which modelled the raw data and 
categorized the number of cells in G1, S, or G2/M-phase. 
 
 
Figure 2.2.5.1: Dotplots of events following flow cytometric acquisition of an 
untreated control sample. Region “R1” selects the Jurkat cell population based on 
Side Scatter (SSC) and Forward Scatter (FSC), while region “R2” excludes cell doublets 
from analysis using FL2-W and FL2-A. 
 
2.2.6 Western Blotting 
Western Blotting is a technique which can determine the expression of proteins in 
extracts or cell lysates, by detecting the fluorescence of antibodies which bind to the 
epitope of the protein of interest.  
 
2.2.6.1 Protein Extraction 
A suspension of Jurkat cells was prepared as per Section 2.2.2, and aliquoted into a 
12 well flat-bottomed plate (600 µL; 1.5x106 cells/well). The lignan compounds were 
prepared as per Section 2.2.1, and 600 µL of each concentration was added to the 
appropriate cell suspensions at a final concentration of 100 µM per well. Additionally, 
Jurkat cells were incubated with 600 µL of 10% RPMI in place of lignan compound 
to act as an untreated control. The plate containing the cells was then incubated at 
37 °C in a 5% CO2 humidified incubator for 4 hours. 
The contents of the wells were replaced in 1.5 mL microcentrifuge tubes, and the 
samples were spun in a centrifuge at 500 x g for 5 minutes at room temperature. The 
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supernatant was discarded, and the pellet was resuspended in 120 µL 
radioimmunoprecipitation assay buffer (RIPA buffer; made in house) containing 
freshly added 1:1000 Protease Inhibitor Cocktail and 1:1000 Phosphatase Inhibitor 
Cocktail (both Sigma, UK). The samples were resuspended using the micropipette, 
and incubated on ice for 15 minutes. The samples were intermittently sonicated for 
10 seconds at room temperature. The samples were spun in a centrifuge at 13,500 
x g at 4 °C for 20 minutes. The lysate was transferred from the samples and replaced 
in chilled 1.5 mL microcentrifuge tubes, and the pellet was discarded. 
 
2.2.6.2 Protein Assay and Quantification 
The concentration of protein in the lysate of each sample was measured using the 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, UK). Known standard 
concentrations of bovine serum albumin (BSA; included in the assay kit) were diluted 
in RIPA extraction buffer to 125-2000 µg/mL, and a blank reference sample 
containing only extraction buffer. A 10 µL volume of each standard and sample lysate 
was placed in a 96 well flat-bottomed plate and mixed with 200 µL working reagent 
(made by combining Reagent A and Reagent B from the assay kit at 50:1 ratio). The 
plate was incubated at 37 °C in a 5% CO2 humidified incubator for 30 minutes. 
Following incubation, the plate was removed and allowed to cool to room 
temperature. The plate was analysed using a Bio-Tek Synergy HT Plate Reader, and 
the absorbance of each sample of unknown protein concentration was compared to 
the absorbance of the known standards at 562 nm. The protein concentration of the 
samples was determined and diluted with extraction buffer appropriately to ensure 
uniform protein concentration across the samples. The samples were then aliquoted 
and stored at -20 °C until required. 
 
2.2.6.3 Gel Electrophoresis and Transfer  
Resolving gels were prepared (as per Section 2.1.5) and were incubated for 45 
minutes at room temperature, covered with a layer of distilled water (dH2O) to prevent 
evaporation. Once set, the layer of water was removed, and the stacking gel (as per 
Section 2.1.5) was poured on top of the resolving gel, with 10-well combs placed in 
the stacking gel. The gels were incubated at room temperature for 20 minutes. 
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The required aliquots of cell lysate were defrosted on ice, and 1 part NuPAGE™ LDS 
4X Sample Buffer (Thermo Fisher Scientific, UK) was added to 3 parts cell lysate. 
The samples were heated at 75 °C for 10 minutes, and then returned to the ice and 
allowed to cool.  
The plates were transferred to a gel tank, and the core was filled with 1X running 
buffer (as per Section 2.1.5) to check for leaking. The tank was filled to the required 
volume with additional 1X running buffer, and the combs were removed from the 
gels. The outer wells on each gel were filled with 5 µL sample buffer, and 5 µL pre-
stained molecular weight marker (Bio-Rad, UK) was added. A 20 µL volume of each 
sample was added to the gels and run at 115 V for 1 hour and 15 minutes at room 
temperature. 
The gels were transferred to nitrocellulose membranes using the TransBlot® Turbo™ 
Transfer System (Bio-Rad, UK) at 25 V (2.5 A) for 7 minutes. 
 
2.2.6.4 Blocking, Antibody Incubation and Detection 
The membranes were blocked for 1 hour using 5% BSA dissolved in Tris Buffered 
Saline (TBS; made in-house) with 0.1 % Tween®-20 (Sigma). The 5% BSA was 
removed, and the membranes were each placed in 50 mL centrifuge tubes and 
incubated with 1:1000 required primary antibody (refer to Section 2.1.5), diluted in 
2.5 % BSA in TBS-Tween. The tubes were continuously rolled at either 4 °C overnight 
or at room temperature for 4 hours. The membranes were washed four times in TBS-
Tween and incubated with 1:5000 required secondary HRP-linked antibody (refer to 
Section 2.1.5) for 1 hour at room temperature. β-Actin was used as the loading 
control for all detections. The membranes were washed four times in TBS-Tween 
and incubated with 1:1 Pierce enhanced chemiluminescence kit (ECL; Thermo Fisher 
Scientific, UK) for 2 min. Excess ECL was drained, and each membrane was 
examined for chemiluminescence using a Bio-Rad Chemidoc Touch Imager. 
 
2.2.6.5 Densitometry 
Western Blot images were analysed using ImageLab software (Bio-Rad, UK). The 
present bands were identified, and the total band volume was calculated.  
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The loading control across each lane was normalised and compared with the volume 
of the bands produced by the protein of interest. Each ratio was compared with the 
ratio of the untreated control sample, thus calculating the relative expression of 
protein. 
 
 
2.3 Statistical Analysis 
Statistical analysis was performed on all data using GraphPad PRISM® version 5.0a 
for Mac. The one-way analysis of variance (ANOVA) was used to compare more than 
two groups of data, and Dunnet’s post-hoc test was chosen to compare each test 
group with the control group. Where significant differences were found, * represents 
a p value <0.05, ** represents a p value <0.01, and *** represents a p value <0.001. 
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3.0 Results 
 
3.1 Effect of novel lignan compound treatment on cellular metabolism of Jurkat 
cells 
 
The metabolic activity of the Jurkat cells after treatment with each lignan compound 
were compared to an untreated control to determine significance (Section 2.2.3). The 
mean absorbances of the treatments were normalised to percentages, using the 
non-viable controls and the untreated controls as 0% and 100% standards, 
respectively. 
 
The metabolic activity of the Jurkat cells when treated with 200 µM of each lignan 
compound following incubation for 24 hours is shown (Figure 3.1.1). Lignan 
compounds SD007, SD010, SD012 and SD013 demonstrated significantly lower 
metabolic activity following treatment (P<0.001) compared to the control. 
Additionally, the metabolic activity of SD008, SD009 and SD014 were shown to be 
significantly decreased (P<0.01), as was SD002, SD006 and SD015 (P<0.05). The 
metabolic activity of the Jurkat cells following a 24 hours incubation with 100 µM of 
lignan compounds SD007 and SD013 were significantly decreased (P<0.001 and 
P<0.01, respectively) from the control (Figure 3.1.2). These were the only lignan 
compounds that significantly affected metabolic activity following treatment at 100 
µM concentration. Treating Jurkat cells with some lignan compounds at 12.5µM 
significantly increased the metabolic activity (Figure 3.1.2 C and D both P<0.05).  
To summarise, treating the Jurkat cells for 24 hours with 200 µM of lignan 
compounds SD007-10 and SD012-15 resulted in a significant reduction of metabolic 
activity. Treating the Jurkat cells for 24 hours with 100 µM of lignan compounds 
SD007 and SD013 also significantly decreased the metabolic activity of the Jurkat 
cells. 
Figure 3.1.2A-D shows lignan compounds SD007, SD008 SD012 and SD013 to give 
a general overview of the varied results after treatment with different concentrations 
of the lignan compounds. Refer to the appendices for the graphs of all lignan 
compounds (Table 7.2), in addition to the absolute metabolic activity values (Table 
7.1). 
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Figure 3.1.1: Metabolic activity of Jurkat cells following treatment for 24 hours 
with 200 µM of each lignan compound. Data is represented as normalised mean, ± 
SEM. Statistical analysis was performed using the one-way ANOVA with Dunnett’s post-
hoc test. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a 
p value < 0.001.  
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Figure 3.1.2: Metabolic activity of Jurkat cells incubated for 24 hours with 12.5-
200 µM of lignan compounds SD007 (A), SD008 (B), SD012 (C) and SD013 (D). 
Data is represented as normalised mean, ± SEM. Statistical analysis was performed 
using the one-way ANOVA with Dunnett’s post-hoc test. * represents a p value < 0.05, 
** represents a p value < 0.01, *** represents a p value < 0.001. 
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The data from the 24-hour time point experiments indicated which lignan 
compounds inhibited the growth of the Jurkat cells. To provide further information 
on the effect of the lignan compounds on the metabolic activity of Jurkat cells, the 
cells were treated for 48 hours. Figure 3.1.3 and 3.1.4 give a general overview of the 
results from this time point, refer to the appendices (Tables 7.4, 7.5 and 7.6) for 
graphs and absolute data for each lignan compound. The metabolic activity of the 
Jurkat cells following treatment with 200 µM of lignan compounds SD002 (Figure 
3.1.4 A), SD003-8, SD010-12, SD014, and SD016-17 was significantly decreased 
(Table 7.4) when compared to the control. Significantly lower metabolic activity was 
also observed when the Jurkat cells were treated with SD001 (P<0.01), SD013 and 
SD018 (P<0.05). Treatment using lignan compound SD015 demonstrated no 
significant reduction in metabolic activity (Figure 3.1.4 B), and the supply of lignan 
compound SD009 had ran out before the experiment took place. 
 
The results show that at 200 µM, there was a significant reduction in metabolic 
activity when treating the Jurkat cells with lignan compounds SD002, SD006-10 and 
SD012-15 when incubating for 24 h. When the Jurkat cells were treated with 100 µM 
of lignan compounds SD007 and SD013, there continued to be a significant 
decrease in metabolic activity (refer to appendices, Tables 7.4 & 7.5). There was also 
an increase in metabolic activity of the Jurkat cells when incubating with lower 
concentrations with some lignan compounds, occasionally significantly (Table 7.5). 
 
Treating the Jurkat cells for 48 hours resulted in a significant decrease in metabolic 
activity when incubating with 200 µM of each lignan compound, with the exception 
of SD015. 
The results from the MTS assays were preliminary data that highlighted which 
particular lignan compounds had anti-cancer potential and were good candidates 
for further research later in the project. 
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Figure 3.1.3: Metabolic activity of Jurkat cells following treatment for 48 hours 
with 200 µM of each lignan compound. Data is represented as normalised mean, ± 
SEM. Statistical analysis was performed using the one-way ANOVA with Dunnett’s post-
hoc test. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a 
p value < 0.001. 
 
 
 
  
 
Figure 3.1.4: Metabolic activity of Jurkat cells incubated for 48 hours with 12.5-
200 µM of lignan compounds SD002 (A) and SD015 (B). Data is represented as 
normalised mean, ± SEM. Statistical analysis was performed using the one-way ANOVA 
with Dunnett’s post-hoc test. *** represents a p value < 0.001. 
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3.2 Effect of lignan compounds on apoptosis and necrosis of Jurkat cells following 
treatment 
 
Results from the MTS assays showed that several lignan compounds had a 
significant effect on cell metabolism, but those that did not could have caused early 
cellular events that do not extrapolate to a change in metabolic activity.  
Following treatment by various concentrations of the lignan compounds for 24 hours, 
the Jurkat cells were prepared for analysis by flow cytometry (Section 2.2.4). The 
Jurkat cell population was selected and gated into four viability stages; viable, early 
apoptotic, late apoptotic and necrotic. Figure 3.2.1 is an example of the flow 
cytometry results following the Annexin V/PI assay and Table 3.2.1 summarises the 
results of the assay following Jurkat cell treatment with the bank of lignan 
compounds. 
 
  
Figure 3.2.1: Dotplots generated by FACSuite showing viable, early apoptotic, late 
apoptotic and necrotic cells of untreated control (A) and treated with 200 µM 
SD007 for 24 hours (B). 
 
 
A B 
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Table 3.2.1: Summary of data following treatment of Jurkat cells with 50-200 µM of each lignan compound for 24 hours. The 
percentage of Jurkat cells in each stage of viability are shown, with significance of the result compared to the untreated control 
indicated if applicable. Refer to the Appendices (Table 7.7) for further information. Data is represented as mean, statistical analysis 
was performed using the one-way ANOVA with Dunnett’s post-hoc test. * represents a p value < 0.05, ** represents a p value < 0.01, 
*** represents a p value < 0.001. 
Lignan Viable Early Apoptotic Late Apoptotic Necrotic 
 50 µM 100 µM 200 µM 50 µM 100 µM 200 µM 50 µM 100 µM 200 µM 50µM 100 µM 200 µM 
SD001 86.4% 83.4% 73.4% 6.2% 8.2% 18.4%*** 5.3% 6.6% 7.1% 2.1% 1.8% 1.1% 
SD002 84.8% 85.6% 68.3%* 5.9% 6.8% 22.5%*** 6.1% 5.8% 8.5% 3.2% 1.8% 0.8% 
SD003 83.9% 80.9% 74.1% 9.5% 11.6%** 17.7%*** 5.1% 6.3% 6.7% 1.5% 1.3% 1.5% 
SD004 76% 78.2% 68.1% 9.8% 9.5%* 17%*** 13.2% 11.5% 13.8% 1.1% 0.7% 1.1% 
SD005 82.4% 83.6% 64.3% 6.7% 6.5% 17.8%*** 5.4% 4.5% 11.2% 5.7% 5.1% 6.7% 
SD006 78.8% 79.2% 72.5% 8.2% 8.1% 12.7%*** 11.2% 10.9% 13.2% 1.9% 1.8% 1.6% 
SD007 75.9% 72.4%** 5.8%*** 10.6%* 10% 27%*** 10.6% 14% 62.8%*** 3.2% 3.6% 1.2% 
SD008 73.9% 73.9% 49.8%*** 12%** 11.8%** 28.5%*** 12.5% 12.9% 20.6%*** 1.7% 1.4%*** 1.1% 
SD009 72.8% 72.6% 46.5%*** 13.2%** 13.2%** 35.2%*** 12.5% 12.8% 17.7%** 1.5% 1.4% 0.7% 
SD010 70.7% 62.1%** 46.3%*** 14.4%* 17%** 24.8%*** 13.5% 19.6%* 27.9%*** 1.5% 1.3% 1%* 
SD011 75.8% 76.2% 76.3% 10.7%** 11.7%*** 12.2%*** 10.5% 9.7% 10.6% 3% 2.5% 0.9% 
SD012 72.6%*** 65.7%*** 35.9%*** 7.2%* 8.1%*** 13.7%*** 19%*** 24.1%*** 49%*** 1.3% 2.1%* 1.4% 
SD013 74.9%*** 41.2%*** 34.4%*** 11.7%*** 15.6%*** 16.4%*** 12.8** 40.7*** 44.2*** 0.6 2.5* 5%*** 
SD014 75.9%*** 72.3%*** 55%*** 12.4%*** 11.5%*** 7.3%** 10.5% 14.6%** 34.6%*** 1.2% 1.5% 3%** 
SD015 79.8%* 76.4%*** 76%*** 11.3%** 12.2%** 8.7%*** 8.4% 10.6% 14.6%*** 0.5%* 0.8% 0.8% 
SD016 74.9%*** 69.8%*** 67.2%*** 17.2%*** 18.7%*** 13.5%*** 7% 10% 17.9%*** 0.9% 1.5% 1.4% 
SD017 87.5% 83.7% 84.5% 5.4% 7.9% 8.5% 6% 7.3% 6.3% 1.1% 1.1%*** 0.7%*** 
SD018 67.8%*** 47.2%*** 37.4%*** 23.3%*** 18.2%*** 19.7%*** 8.5% 33%*** 40.5%*** 0.4% 1.7% 2.4%** 
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There was a significant decrease in the percentage of viable cells compared to the 
control following treatment of the Jurkat cells with 200 µM of lignan compounds 
SD002, SD007-10, SD012-16 and SD018 (refer to appendices Table 7.7 for absolute 
values). Treating the Jurkat cells with 100 µM of lignan compounds SD007, SD010, 
SD012-16 and SD018 showed a significantly reduced percentage of viable Jurkat 
cells. Furthermore, treatment with 50 µM of lignan compounds SD012-16 and SD018 
continued to significantly reduce the percentage of viable Jurkat cells (Table 3.2.1; 
Figures 3.2.3-3.2.6).  
 
The percentage of early apoptotic cells was significantly higher than the untreated 
control when the Jurkat cells were treated with 200 µM of lignan compounds SD001-
16 and SD018. Following treatment with 100 µM of lignan compounds SD003, 
SD004, SD008-16 and SD018, the percentage of early apoptotic Jurkat cells was 
also significantly increased. There was also a significantly increased percentage of 
early apoptotic Jurkat cells when treated with 50 µM of lignan compounds SD007-
16 (Table 3.2.1; Figures 3.2.2-3.2.6). 
 
The percentage of Jurkat cells in late apoptosis following treatment with 200 µM of 
lignan compounds SD007-10, SD012-16 and SD018 was significantly increased 
compared to the untreated control. Following treatment with 100 µM of lignan 
compounds SD010, SD012-14 and SD018, there was a significant increase in late 
apoptotic Jurkat cells. Treatment with 50 µM of lignan compounds SD012 and 
SD013 showed a significantly increased number of late apoptotic Jurkat cells (Table 
3.2.1; Figures 3.2.2-3.2.6).  
 
The percentage of necrotic Jurkat cells was significantly decreased compared to the 
untreated control following treatment with 200 µM of lignan compounds SD010 and 
SD017, 100 µM of lignan compound SD017 and 50 µM of lignan compound SD015. 
The percentage of necrotic Jurkat cells significantly increased following treatment 
with 200 µM lignan compounds SD013-14 and SD018. A significant increase in the 
percentage of necrotic Jurkat cells was also observed following treatment with 100 
µM of lignan compounds and SD012 and SD013 (Table 3.2.1; Figures 3.2.3-3.2.4). 
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 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. n.s. *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable n.s. n.s. * 
Early Apoptotic n.s. n.s. *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
  
 
 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. ** *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. * *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
Figure 3.2.2: Stages of Jurkat cell viability following treatment for 24 hours with 
50-200 µM of lignan compounds SD001 (A), SD002 (B), SD003 (C) and SD004 (D). 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001.  
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 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. n.s. *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. n.s. *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
 
 
 
 
 50µM 100µM 200µM 
Viable n.s. ** *** 
Early Apoptotic * n.s. *** 
Late Apoptotic n.s. n.s. *** 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable n.s. n.s. *** 
Early Apoptotic ** ** *** 
Late Apoptotic n.s. n.s. *** 
Necrotic n.s. n.s. n.s. 
 
 
Figure 3.2.3: Stages of Jurkat cell viability following treatment for 24 hours with 
50-200 µM of lignan compounds SD005 (A), SD006 (B), SD007 (C) and SD008 (D). 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001. 
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 50µM 100µM 200µM 
Viable n.s. n.s. *** 
Early Apoptotic ** ** *** 
Late Apoptotic n.s. n.s. ** 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable n.s. ** *** 
Early Apoptotic * ** *** 
Late Apoptotic n.s. * *** 
Necrotic n.s. n.s. * 
    
 
 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic ** *** *** 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. n.s. n.s. 
 
 50µM 100µM 200µM 
Viable *** *** *** 
Early Apoptotic * *** *** 
Late Apoptotic *** *** *** 
Necrotic n.s. * n.s. 
 
Figure 3.2.4: Stages of Jurkat cell viability following treatment for 24 hours with 
50-200 µM of lignan compounds SD009 (A), SD010 (B), SD011 (C) and SD012 (D). 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001. 
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Early Apoptotic *** *** *** 
Late Apoptotic ** *** *** 
Necrotic n.s. * *** 
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Viable *** *** *** 
Early Apoptotic *** *** ** 
Late Apoptotic n.s. ** *** 
Necrotic n.s. n.s. ** 
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Viable * *** *** 
Early Apoptotic ** ** *** 
Late Apoptotic n.s. n.s. *** 
Necrotic * n.s. n.s. 
 
 50µM 100µM 200µM 
Viable *** *** *** 
Early Apoptotic *** *** *** 
Late Apoptotic n.s. n.s. *** 
Necrotic n.s. n.s. n.s. 
 
Figure 3.2.5: Stages of Jurkat cell viability following treatment for 24 hours with 
50-200 µM of lignan compounds SD013 (A), SD014 (B), SD015 (C) and SD016 (D). 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001. 
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 50µM 100µM 200µM 
Viable n.s. n.s. n.s. 
Early Apoptotic n.s. n.s. n.s. 
Late Apoptotic n.s. n.s. n.s. 
Necrotic n.s. *** *** 
 
 50µM 100µM 200µM 
Viable *** *** *** 
Early Apoptotic *** *** *** 
Late Apoptotic n.s. *** *** 
Necrotic n.s. n.s. ** 
 
Figure 3.2.6: Stages of Jurkat cell viability following treatment for 24 hours with 
50-200 µM of lignan compounds SD017 (A) and SD018 (B). Data is represented as 
mean ± SEM. Statistical analysis was performed using the one-way ANOVA, with 
Dunnett’s post-hoc test used to compare samples with the untreated control. * 
represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p value < 
0.001. 
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3.3 Effect of novel lignan compound treatment on the cell cycle distribution of 
Jurkat cells following treatment 
 
The results of the apoptosis and necrosis assay indicated that a number of lignan 
compounds induced cell death by apoptosis rather than necrosis. To identify which 
phase of the cell cycle the Jurkat cells were being apoptosed, the DNA content of 
the nucleus of each Jurkat cell was measured using flow cytometry (Section 2.2.5). 
Following treatment, the Jurkat cells were prepared for analysis by flow cytometry. 
Cell cycle analysis produced a histogram and a breakdown of the percentage of 
Jurkat cells in each phase of the cell cycle (Figure 3.3.1). 
 
When the Jurkat cells were treated with 100 µM of each lignan compound for 4 h, 
there was no significant change in the percentage of cells fixed in G1-phase or in S-
phase compared to the untreated control (Figure 3.3.2 and Figure 3.3.3, 
respectively). 
The percentage of Jurkat cells fixed in G2-phase was significantly lower (P<0.001) 
following incubation with 100 µM of lignan compounds SD007, SD008, SD010, 
SD012, SD013, SD014, SD015, SD016 and SD018 for 4 hours when compared to 
the untreated control (Figure 3.3.4). Refer to the Appendices (Table 7.8) for absolute 
values. 
 
As a positive control, the Jurkat cells were treated with 0.5 µM camptothecin for 4 
hours in place of the lignan compounds. The percentage of Jurkat cells in G1-phase 
was significantly increased compared to the untreated control (Figure 3.3.2). The 
mean percentage of Jurkat cells in S-phase was significantly decreased compared 
to the untreated control (Figure 3.3.3). The mean percentage of Jurkat cells fixed in 
G2-phase were significantly decreased compared to the untreated control (Figure 
3.3.4) Refer to the Appendices (Table 7.9) for absolute values. 
 
To summarise, none of the lignan compounds showed any significant effect on the 
mean number of Jurkat cells in G1-phase and S-phase, however lignan compounds 
SD007-8, SD010, SD012-16 and SD018 showed a significant decrease in the mean 
percentage of Jurkat cells in G2-phase, which suggests the Jurkat cells are 
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undergoing cell death before reaching G2-phase. Refer to the Appendices (Table 
7.10) for absolute values. 
 
 
 
 
 
Figure 3.3.1: Cell cycle analysis of Jurkat cells following no treatment (A) and a 4-
hour treatment with 100 µM SD007 (B), using ModFit LT software. The histogram 
shows the number of Jurkat cells in G1, S and G2/M-phase measured by the area of 
fluorescence detected using the FL2 channel. A brief analysis of each sample is shown. 
A detailed analysis is also generated by the software, quantifying the number of cells in 
each phase (not pictured). 
 
 
 
 
 
A B 
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Figure 3.3.2: Mean percentage of Jurkat cells in G1 following treatment for 4 hours 
with 100 µM of each lignan compound. As a positive control, Jurkat cells were 
treated with 0.5 µM camptothecin for 4 hours. Data is represented as mean ± SEM. 
Statistical analysis was performed using the one-way ANOVA, with Dunnett’s post-hoc 
test used to compare samples with the untreated control. *** represents a p value < 
0.001. 
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Figure 3.3.3: Mean percentage of Jurkat cells in S-phase following treatment for 
4 hours with 100 µM of each lignan compound. As a positive control, Jurkat cells 
were treated with 0.5 µM camptothecin for 4 hours. Data is represented as mean ± 
SEM. Statistical analysis was performed using the one-way ANOVA, with Dunnett’s 
post-hoc test used to compare samples with the untreated control. *** represents a p 
value < 0.001. 
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Figure 3.3.4: Mean percentage of Jurkat cells in G2/M-phase following treatment 
for 4 hours with 100 µM of each lignan compound. As a positive control, Jurkat 
cells were treated with 0.5 µM camptothecin for 4 hours. Data is represented as 
mean ± SEM. Statistical analysis was performed using the one-way ANOVA, with 
Dunnett’s post-hoc test used to compare samples with the untreated control. *** 
represents a p value < 0.001. 
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3.4 Effect of novel lignan compounds on cell signalling and stress response in 
Jurkat cells following treatment 
 
The Jurkat cells were treated with 100 µM of lignan compounds SD007, SD010, 
SD011, SD012, SD013 and SD018 for 4 hours.  
Due to time constraints, a selection of lignan compounds were chosen for this 
investigation based on the results obtained from previous experiments (Sections 3.1-
3.3). Lignan compounds SD007, SD010, SD012, SD013 and SD018 appeared to 
significantly increase the rate of apoptosis in the Jurkat cells following treatment, 
unlike SD011, which did not appear to have any significant pro-apoptotic effect on 
the Jurkat cells (Figure 3.2.4). Thus, comparing the results of the pro-apoptotic 
lignans on cell signalling and stress response with those of SD011 would indicate 
whether the Wnt/β-catenin or Akt/PI3K pathways are responsible for the pro-
apoptotic properties of lignan compounds SD007, SD010, SD012, SD013 and 
SD018. 
The lysates from the treated Jurkat cells were analysed for the presence of HSPB1, 
HSPA1A, Akt, phospho-Akt and phospho-β-catenin by Western Blotting. 
 
When compared to the relative HSPB1 expression in the untreated control (1.00), 
there was a fold increase of 7.15, 2.11, 2.14, 2.17, 1.98 and 2.19 when the Jurkat 
cells were treated with 100 µM of lignan compounds SD007, SD010, SD011, SD012, 
SD013 and SD018, respectively (Figures 3.4.1 and 3.4.2).  
There was a fold decrease of 0.92 in relative HSPA1A expression compared to the 
untreated control (1.00) when treating the Jurkat cells with 100 µM of lignan 
compound SD007 for 4 h. Identical treatment with lignan compounds SD010, SD011, 
SD012, SD013 and SD018, demonstrated a fold increase of 1.44, 1.23, 18.25, 1.74 
and 1.65 respectively (Figures 3.4.3 and 3.4.4). 
Phospho-Akt levels were shown to decrease after a 4h treatment with 100 µM of 
lignan compounds SD007 (0.03), SD010 (0.90), SD011 (0.20), SD012 (0.02), SD013 
(0.015) and SD018 (0.13) when compared to the untreated control (1.00; Figures 
3.4.5 and 3.4.6). 
When compared to the relative Akt expression in the untreated control (1.00), there 
was a fold increase of 1.52, 1.66, 1.23 and 1.01 when the Jurkat cells were treated 
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with 100 µM of lignan compounds SD007, SD010, SD011 and SD012, respectively. 
Identical treatment with lignan compounds SD013 and SD018 resulted in a fold 
decrease of 0.86 and 0.75, respectively (Figures 3.4.7 and 3.4.8). 
Bands for phospho-β-catenin were not observed on the membrane following 
chemiluminescent detection (Figure 3.4.9). 
 
In summary, the lignan compounds, particularly SD007, appeared to affect the 
expression of HSPB1, with a small increase in HSPA1A expression also observed. 
There was also a large fold increase in HSPA1A expression following treatment with 
lignan compound SD012. The effect of the lignan compounds on phospho-Akt, Akt 
and phospho-β-catenin expression however did not appear to change, suggesting a 
minimal effect on these cell signalling pathways.  
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 SD007 SD010 SD011 SD012 SD013 SD018 Control  
Figure 3.4.1: Western Blot images of HSPB1 levels (A) and β-actin levels (B) 
using protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
 
 
 
Figure 3.4.2: Density results showing relative protein expression of HSPB1 in the 
lignan compound treated samples compared to the untreated control. 
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 SD007 SD010 SD011 SD012 SD013 SD018 Control  
 
 
Figure 3.4.3: Western Blot images of HSPA1A levels (A) and β-actin levels (B) 
using protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
 
 
Figure 3.4.4: Density results showing the relative protein expression of HSPA1A in 
the lignan compound treated samples compared to the untreated control. 
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 SD007 SD010 SD011 SD012 SD013 SD018 Control  
 
 
 
 
Figure 3.4.5: Western Blot images of phospho-Akt levels (A) and β-actin levels 
(B) using protein extracts from Jurkat cells treated for 4 hours with 100 µM of 
lignan compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an 
untreated control. 
 
 
Figure 3.4.6: Density results showing the relative protein expression of phospho-
Akt in the lignan compound treated samples compared to the untreated control. 
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 SD007 SD010 SD011 SD012 SD013 SD018 Control  
 
Figure 3.4.7: Western Blot images of Akt levels (A) and β-actin levels (B) using 
protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
 
Figure 3.4.8: Density results showing the relative protein expression of Akt in the 
lignan compound treated samples compared to the untreated control. 
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 SD007 SD010 SD011 SD012 SD013 SD018 Control  
 
 
 
Figure 3.4.9: Western Blot images of phospho-β-catenin levels (A) and β-actin 
levels (B) using protein extracts from Jurkat cells treated for 4 hours with 100 
µM of lignan compounds SD007, SD010, SD011, SD012, SD013 and SD018, and 
an untreated control. 
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4.0 Discussion 
 
The purpose of the project was to identify whether the novel lignan compounds could 
have a role as anti-leukaemia agents. As previously mentioned, both natural and 
synthetic lignans have been described as possessing anti-cancer properties in in-
vitro studies, in addition to well-established treatment regimens involving the 
chemotherapeutics etoposide and teniposide (Gordaliza et al., 2000). In order for 
new treatments to be licensed and used in recognised protocols, it is crucial that the 
full effects and mechanisms of the compounds are elucidated, the first stage of 
which involves assessing in-vitro effects on suitable cell models. The exact mode of 
cytotoxicity should be identified, as the pro-inflammatory effect of a necrosis-
inducing drug could exacerbate collateral damage to non-tumour cells when 
compared to a relatively ‘clean’ pro-apoptotic treatment (Chandrashekar and 
Shobha Rani, 2008). Some potential chemotherapeutics may not induce cell death 
at all and could cause the cancer cells to enter a cytostatic state where further 
proliferation is inhibited, but the cells remain in-situ until removal by the innate 
immune system (Medon et al., 2017). 
It is important to ensure that the new drug targets the cancer cell with minimal 
disruption or stresses to healthy tissues. While the treatment could be effective 
against the malignant cell, an undesirable effect towards the healthy vascular 
endothelium or gastrointestinal tract would not only affect the route of 
administration, but also the dosage required (Chandrashekar and Shobha Rani, 
2008). Research surrounding the aberrant deregulation of signalling pathways in 
cancer cells, has highlighted that upstream and downstream components are a 
desirable target for novel anti-cancer therapies.  
 
4.1 Investigating the effect of novel lignan compounds on cellular metabolism of 
Jurkat cells following treatment 
MTS assays were used in this study to assess the effect of the novel lignan 
compounds on Jurkat biochemical activity. The metabolic activity of the Jurkat cells 
following treatment varied with each individual lignan compound.  
Jurkat cell treatment with 200 µM of the lignan compounds SD002, SD006-10, and 
SD012-15 demonstrated a significant reduction in metabolic activity after a 24-hour 
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incubation. The same experiment also resulted in reduced metabolic activity after a 
24-hour treatment with 100 µM of lignan compounds SD007 and SD013. This 
suggested that lignan compounds SD007 and SD013 were the most potent, as they 
significantly decreased cell metabolism at lower concentrations than the other lignan 
compounds. Following a 48-hour treatment with 200 µM of these same lignan 
compounds, there was a significant reduction in metabolic activity, with the 
exception of lignan compound SD015. 
Treatment with 200 µM of lignan compounds SD001, SD003-5, SD011 and SD016-
18 did not have a significant effect on the metabolic activity of the Jurkat cells after 
24 hours, suggesting that these particular compounds were not effective anti-
leukaemia agents. However, following a 48-hour incubation with the same lignan 
compounds, a significant decrease in metabolic activity was observed, highlighting 
the importance of including time-course experiments in such research. 
Surprisingly, incubation of the Jurkat cells with lower concentrations of some lignan 
compounds (SD012 and SD013) resulted in an increase in metabolic activity when 
compared with the untreated cells, with this increase being statistically significant for 
some lignan compounds (Figure 3.1.2, Table 7.2 and Table 7.5). Cells may increase 
their rate of metabolism during cellular stress as they upregulate expression of key 
stress and anti-apoptotic genes and proteins (Jeon et al., 2011). These results 
highlight that even at low concentrations, some of the lignan compounds are exerting 
an effect on this cell model. 
The data from the 48-hour time point suggests that treatment with 200 µM of all 
lignan compounds – with the exception of SD015 – significantly reduces metabolic 
activity. The data also supports the data from the 24-hour time point with regards to 
treatment with 100 µM of lignan compounds SD007 and SD013, where there is also 
a significant decrease in metabolic activity (Table 7.5).  
One of the limitations of proliferation assays such as MTS, is that they are unable to 
distinguish between cytotoxicity and cytostasis. The principle of this colorimetric 
assay is that biochemically active cells will metabolise the tetrazolium compound to 
produce a formazan compound, which is directionally proportional to the 
absorbance of the solution at 450nm. Whether a cell has simply ceased proliferation 
or undergone cell death, biochemical reduction of the tetrazolium salt will cease.  
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One of the difficulties in comparing the present data with that from other published 
research is the frequent over-simplification of the published data. The MTT and MTS 
assays are often incorrectly described as cytotoxicity assays, suggesting that the 
assays are able to distinguish between cytotoxic and cytostatic cells. This means 
that many studies describe the anti-cancer chemotherapeutics under investigation 
as cytotoxic, despite cytostasis being the direct effect of the compound. An example 
of this is an article by Gordaliza et al. (2000), which incorrectly describes the 
cytostatics etoposide and teniposide as cytotoxic agents.  
A study conducted by Yoo et al. (2010) using a colon cancer cell line (SW480) to 
investigate the effect of a 48 hours incubation with the natural lignans arctiin, 
matairesinol and arctigenin used a viability assay to analyse cell survival, albeit with 
a different product known as EZ-CyTox. This experiment showed that following a 
48-hour incubation, cell survival was significantly decreased with 50 µM of each 
lignan. This experiment adds further weight to the possibility that a longer incubation 
time with the lignan compounds could influence cell viability. Additionally, a study by 
He et al. (2013) investigated the treatment of the colorectal cancer cell lines Caco-2, 
SW1116 and HCT-116 with the lignan wogonin at 0-200 µM for 6 hours, 12 hours 
and 24 hours using the MTT assay. However, unlike the study by Yoo et al. (2010), 
statistical analysis was not performed on this set of data therefore it is difficult to 
compare with other experiments. 
 
The MTS assay data are particularly valuable as preliminary results, indicating not 
only which particular lignan compounds are the most effective at reducing 
biochemical activity, but also the concentration at which the lignan compounds may 
achieve this effect. The results highlighted lignan compounds SD002, SD006-10 and 
SD012-15 as the most potent treatments, with SD007 and SD013 showing a 
significant effect even at 100 µM.  
 
4.2 Effect of lignan compounds on apoptosis and necrosis of Jurkat cells following 
treatment 
The Annexin V/PI assay is a useful flow cytometric method that is able to quantify 
the number of viable, early apoptotic, late apoptotic and necrotic cells within a 
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sample. This technique elaborates on the data previously collected from the MTS 
assays, by using apoptosis and necrosis markers to indicate the mode of cell death. 
The Annexin V/PI assay confirms that cell death is occurring following treatment with 
some of the lignan compounds. The assay also suggests that the more effective 
lignan compounds do not act as cytostatic agents, but exhibit cytotoxic properties, 
owing to the presence of apoptotic and necrotic markers in the treated cells. The 
results indicated that lignan compounds SD007-10, SD012-16 and SD018 are of 
particular interest; however, each of these lignan compounds affect the Jurkat cells 
in different ways. For example, SD007 produced both an extremely vivid decrease 
in viable cells and increase in apoptosis only at a higher concentration of 200 µM 
and appeared to be much less potent after a 100 µM treatment (Figure 3.2.1 and 
3.2.3C). However, lignan compounds SD012-14 and SD018 had a relatively modest 
but significant effect on Jurkat cell viability and apoptosis at both 200 µM and 100 
µM (Figures 3.2.4D, 3.2.5A, 3.2.5B and 3.2.6B, respectively). 
 
He et al. (2013) used the Annexin V/PI assay to examine the effect of the flavanoid 
wogonin on HCT-116 cells, albeit at the lower concentrations of 10 µM, 20 µM and 
40 µM for 24 hours, which showed no significant alterations in the populations. The 
authors have also opted not to publish the exact method used to obtain the results 
of the assay, as it is only briefly mentioned in the caption of Figure 1 that the method 
is an Annexin V/PI stain. It is therefore difficult to compare this particular experiment 
with my own, as there is not enough information included in the article. There is also 
no mention in the study of why the lower concentrations of wogonin (10 µM, 20 µM 
and 40 µM) were chosen rather than higher concentrations.   
A study published by Peuhu et al. (2013) investigating the inhibition of Akt signalling 
with the lignan matairesinol in a prostate cancer cell line (LNCaP) but did not use the 
Annexin V/PI assay as used in my study and in the study by He et al (2013). The 
method used by Peuhu et al. is traditionally used to quantify the amount of DNA in 
cells for cell cycle analysis, however sub-G1 levels of DNA from apoptosed cells 
within the sample are also able to be detected. This is less specific than the Annexin 
V/PI assay used in my study for determination of apoptosis, as it is not possible to 
differentiate between early and late apoptosis with just the sub-G1 levels of DNA 
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quantified in the samples, therefore it is difficult to compare the data between 
studies. 
 
4.3 Effect of lignan compound treatment on the cell cycle of Jurkat cells following 
treatment 
The flow cytometric cell cycle analysis assay is used to distinguish cells by 
quantifying the amount of DNA in each cell. The analysis gives an indicator as to the 
percentage of Jurkat cells that are in either G1, S, or G2/M-phase following lignan 
compound treatment.  
The results from the assay provide some interesting details regarding the activity of 
the lignan compounds. None of the lignan compounds had any significant effect on 
the mean percentage of Jurkat cells in either G1 or S-phase, however there was a 
significant decrease in the percentage of Jurkat cells in G2/M-phase following 
treatment with lignan compounds SD007, SD008, SD010, SD012-16, and SD018. 
These particular lignan compounds were highlighted as potential pro-apoptotic 
agents in the Annexin V/PI assay. The significant reduction in Jurkat cells in G2/M-
phase adds further weight to the suggestion that following treatment with these 
lignan compounds in particular the cells undergo apoptosis either during or before 
mitotic division.  
However, this data also appears to suggest that the lignan compounds do not affect 
the Wnt/β-catenin pathway, which plays an important role in the regulation of the cell 
cycle. The study conducted by Yoo et al. (2010) showed that a 24-hour treatment 
with 100 µM arctigenin on the SW480 cells induced a significant increase in G2/M-
phase cells and a significant decrease in G1-phase cells. The same study 
demonstrated that the Wnt/β-catenin pathway was downregulated following a 100 
µM arctigenin treatment, which does not correlate with the cell cycle data also 
published in the study by Yoo et al. Another project investigated the effect of a 
flavonoid on the Wnt/β-catenin pathway in HCT116 cells, and in contrast to the study 
by Yoo et al., demonstrated that the cells were arrested in G1-phase, while also 
downregulating the activity of the Wnt/β-catenin pathway (He et al., 2013). 
Additionally, in another study, a G1-phase arrest was achieved using a natural lignan 
in a breast cancer cell line (T47D) which also inhibited the Wnt-β-catenin pathway 
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downstream target cyclin D1 (Kim et al., 2010). It is important to note however, that 
Yoo et al., He at al. (2013), and Kim et al. (2010) incubated the cell lines with the 
treatments for up to 24 h, which is longer than the drug-exposure times used in the 
present, in which Jurkat cells, which were only incubated with the lignan compounds 
for 4 h. The research published by Peuhu et al. included cell cycle data, which also 
showed that the LNCaP cells were arrested in G1-phase, which implies that there 
was no interference with the PI3K/Akt signalling cascade. 
 
4.4 Effect of novel lignan compounds on cell signalling and stress response in 
Jurkat cells following treatment 
 
Western Blotting was used to detect the presence of proteins of interest within 
lysates of the lignan compound treated Jurkat cells. Densitometry analysis was then 
used to calculate the fold change in protein expression compared with the untreated 
Jurkat cells. 
The Western Blot and densitometry results for HSPB1 expression suggest that 
following a 4-hour incubation with 100 µM of lignan compound SD007, there was an 
approximately 7-fold increase in expression. There was also a 2-fold increase in 
HSPB1 following the same treatment with lignan compounds SD010, SD011, SD012, 
SD013 and SD018. The results for HSPA1A expression suggested relatively few 
changes following lignan treatments, with the exception of SD012, which appeared 
to induce a 17-fold increase in expression. 
The densitometry results indicated there was relatively little fold change in Akt or p-
Akt expression, if any. Also, no bands were observed during Western Blot detection 
for p-β-catenin. 
Increased HSPB1 expression after treatment with the lignan compounds suggests 
the Jurkat cells were undergoing a cellular stress response to the lignan treatment. 
One of the functions of HSPB1 is to inactivate the caspase cascade by binding with 
caspase-3 and cytochrome c, thus inhibiting the apoptotic pathway (Wang et al., 
2014; Acunzo et al., 2012). HSPB1 is therefore highly induced in cells undergoing a 
survival response to cytotoxic stimuli. This increased HSPB1 level suggests that 
lignan compound SD007 is inducing apoptosis in the Jurkat cells and that the cells 
are responding by upregulating HSPB1 to ensure cell survival. Lignan compound 
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SD007 shows the largest fold increase, which is consistent with the Annexin V/PI 
data, where the lignan compound induced significant apoptosis at 200 µM. It would 
be interesting to investigate the HSPB1 levels after longer time points following 
lignan treatment, as the Annexin V/PI data indicates apoptotic activity despite the 
strong induction of HSPB1 in the cells. It is important to note that Western Blot 
analysis was only performed on lysates from Jurkat cells treated at 100 µM 
concentrations for 4 hours. However, the striking effects of this lignan in comparison 
with others when considering the MTS and Annexin V/PI data make it plausible to 
assume that HSPB1 may also be strongly induced following higher concentrations 
of the compound. The 17-fold increase in HSPA1A expression following SD012 
treatment is an interesting result. Although SD012 was an effective apoptotic agent 
at 100 µM in previous experiments (Figure 3.2.4D), the result is not entirely consistent 
as lignan compounds SD013, SD014 and SD018 returned similar results following 
the Annexin V/PI assay (Section 3.2) however did not demonstrate HSPA1A 
induction. It is possible that SD012 is a much stronger HSPA1A inducer than other 
lignan compounds, however further examination is necessary to elucidate this. The 
result could also be attributed to the uneven shape of the bands, leading to them not 
being measured correctly during densitometry analysis. Unfortunately, there is 
limited literature investigating the effects of lignans on heat shock protein expression 
in cancer. In contrast to the experimental data, a study investigating the effect of 
arctigenin on the heat shock response showed that a 3 hour incubation of cervical 
cancer cells (HeLa) with 100 µM arctigenin suppressed the expression of HSPA1A 
(Ishihara et al., 2006). Another comparable study investigated the effect of the oral 
administration of the lignan schisandrin B on HSPB1 and HSPA1A expression in 
mice with hepatic injury. This study showed a significant increase in the expression 
of both HSPB1 and HSPA1A (Li et al., 2014).  
The anti-apoptotic properties of HSPB1 and HSPA1A have been strongly associated 
with chemotherapy resistance in cancer cells (Wang et al., 2014). Yamamoto et al. 
(2001) compared the levels of HSPB1 and HSPA1A between a cisplatin resistant and 
cisplatin sensitive ovarian cancer cell line and identified upregulated HSPB1 and 
HSPA1A in the cisplatin resistant cells. Increased HSPA1A levels have also been 
observed in relapsed CML patients that are refractory to imatinib mesylate (Zorzi & 
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Bonvini, 2011).  These studies suggest that the increased HSPB1 expression 
observed in the Jurkat cells following lignan compound treatment, especially when 
treated with SD007, could be associated with chemotherapy resistance, which could 
mean any surviving Jurkat cells could become resistant to future courses of 
treatment.  
 
The relatively subtle changes in expression of p-Akt and Akt suggest that the lignan 
compounds do not affect the PI3K/Akt pathway. Further evidence is the cell cycle 
analysis (Section 4.3), which did not show an increase in the number of cells arrested 
in G1-phase as a previous study by Peuhu et al. where Akt signalling decreased in 
response to treatment of LNCaP cells by the natural lignan matairesinol. However, 
as LNCaP cells are a prostate carcinoma cell line and matairesinol is a different 
lignan, these could be legitimate reasons for the differences in data. Additionally, the 
same research group identified the lignan nortrachelogenin as possessing the same 
properties in-vitro (Peuhu et al., 2013). 
The absence of bands on the Western Blot probed for p-β-catenin, in addition to the 
aforementioned cell cycle data (Section 4.3), indicates that the Wnt/β-catenin 
pathway is not affected by the lignan compounds. The study by Yoo et al., which 
described regulation of the Wnt/β-catenin pathway following arctigenin treatment, 
used SW480 cells rather than Jurkat which could explain the contrasting results. 
Additionally, as mentioned in Section 4.3, the cell cycle data conflicted with other 
published papers, as well as the vague descriptions of the results within the article 
by the authors.  
 
4.5 Future Work 
The experiments conducted have indicated that the lignan compounds show 
promise as anti-cancer agents, in particular lignan compounds SD007, SD013 and 
SD018. It is interesting to note, that these three lignan compounds were the only 
compounds which did not contain a methyl (MeO) group at any of the molecules side 
chains. 
It would be useful to perform additional cell cycle analysis could be performed to 
determine the effects of the lignans at different concentrations, as well as at following 
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longer treatment durations. Yoo et al., He at al., and Kim et al. obtained significant 
data by incubating the cells with the polyphenolic compounds for 24 hour before 
performing cell cycle analysis, which suggests this could be an interesting time point 
to observe changes in cell cycle. It would also be useful to perform Western Blots on 
lysates at this same 24 hour time point. However it was difficult to extract protein 
from Jurkat cells treated with lignan compound SD007, as the cells were undergoing 
apoptosis before protein was extracted. Conversely, in the study of phosphorylation 
events, it may be beneficial to reduce the treatment duration of cells in order to 
capture these events which can happen within minutes, before de-phosphorylation 
of the specific kinase occurs and the window for detection is missed. 
Performing quantitative polymerase chain reaction (qPCR) using mRNA collected 
from lignan compound-treated cells in future work would allow detailed examination 
of the effects of these compounds on key signalling and stress response genes, 
which would support protein analysis work by the Western Blot. For example, it 
would be interesting to look at HSPA1A and HSPB1 gene expression after lignan 
compound treatment, which could confirm the effect of the lignan treatment on 
HSPB1 and HSPA1A expression. It would also be beneficial to investigate the 
expression of target genes involved in cell signalling pathways. 
In addition to the Wnt/β-catenin and PI3K/Akt pathways investigated in this thesis, 
other pathways that could be of interest are the NOTCH pathway, which is heavily 
implicated in T-cell development, as well as the JAK/STAT pathway (Willis, 2011; 
Zhou et al., 2013). 
Additional in-vitro studies could be conducted with other leukaemia cell lines, such 
as B-cell malignancies, as well as primary cells obtained from patients with 
leukaemia would be a useful step in the pre-clinical development of the compounds. 
When considering moving any compound forward into in-vivo studies, the effects of 
in-vivo metabolism on the activity of the compound need consideration. Many 
compounds may be metabolised by the liver into products that have differing activity 
from that of the original compound. While still in the in-vitro stage of testing, liver 
microsomes can be used as a source of hepatic enzymes to replicate in-vivo 
breakdown of the compound. Future work investigating the metabolism of these 
lignan compounds using liver microsomes would be extremely beneficial. Gut flora 
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metabolism of compounds is an extra consideration when working with lignans. 
Natural lignans are metabolised by gut microflora to produce enterodiol and 
enterolactone (Section 1.4), and this may differ with synthetic lignans. Therefore, 
experiments involving in-vitro metabolism of the compounds using specific gut 
microflora species would also be useful. 
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5.0 Conclusion 
 
The anti-leukaemia potential of the novel lignan compounds were explored, using 
viability and apoptosis assays, analysis of cell cycle distribution and analysis of key 
protein expression. The results indicated that the lignan compounds, SD007, SD008, 
SD010, SD012-16 and SD018 demonstrated pro-apoptotic properties, with SD007, 
SD013 and SD018 of particular interest.  
The data suggested that the lignan compounds had no effect on the regulation of 
the Wnt/β-catenin and PI3K/Akt pathways, thus the effect of the lignan compounds 
on the cell signalling cascades remain elusive.  
The increase of HSPB1 expression following lignan treatment suggested that the 
Jurkat cells were undergoing a cellular stress response which could eventually lead 
to the development of treatment resistance, particularly following treatment with 
lignan compound SD007. 
Subsequent work with these compounds would aim to identify the mechanisms by 
which the lignan compounds induce apoptosis, and to further establish the cellular 
stress induced by the lignan compounds. Despite inducing apoptosis, the induction 
of HSPB1 and HSPA1A by some lignans highlights the need for further research to 
elucidate the usefulness of the lignan compounds. 
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7.0 Appendices 
 
Table 7.1: Absolute data from MTS assay of Jurkat cells treated with 0-200 µM 
lignan compounds SD001-18 for 24 hours. 
SD001 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 85.78024 2.482796 3 
100.000 105.7479 4.211288 2 
50.000 119.2059 13.32042 3 
25.000 102.3546 10.06136 3 
12.500 106.2788 6.751755 3 
0.000 100.0693 11.5026 6 
 
SD002 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 82.5023 6.770195 3 
100.000 93.53646 4.501556 3 
50.000 103.6011 3.13398 2 
25.000 107.6177 0.7835007 2 
12.500 107.964 2.252563 2 
0.000 100.0693 11.5026 6 
 
 
SD003 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 95.57178 4.355972 3 
100.000 102.1411 4.722206 3 
50.000 138.3212 8.154938 2 
25.000 114.9392 8.331841 3 
12.500 112.9927 10.0157 3 
0.000 99.95134 7.302589 6 
 
 
SD004 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 94.2579 4.862274 3 
100.000 112.0681 10.68423 3 
50.000 122.0438 5.448593 3 
25.000 117.9562 4.386871 3 
12.500 113.9659 5.829056 3 
0.000 99.95134 7.302589 6 
 
 
SD005 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 99.70971 3.694611 2 
100.000 122.5447 10.72874 3 
50.000 169.6662 6.362915 2 
25.000 159.5065 3.694641 2 
12.500 183.0188 35.50929 2 
0.000 100.0242 19.01103 6 
 
 
SD006 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 79.86668 7.009827 3 
100.000 107.3333 4.291595 3 
50.000 125.5556 6.32502 3 
25.000 103.4222 11.30531 3 
12.500 109.200 17.91337 2 
0.000 99.95556 3.753914 6 
 
 
SD007 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 -15.06667 2.887522 3 
100.000 54.46667 6.693943 2 
50.000 86.80001 11.86817 3 
25.000 89.91111 4.636734 3 
12.500 109.0222 17.12559 3 
0.000 99.95556 3.753914 6 
 
 
SD008 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 80.07053 5.524315 3 
100.000 88.78307 2.805725 3 
50.000 94.5679 5.398216 3 
25.000 108.1834 8.847427 3 
12.500 110.6526 1.165634 3 
0.000 100.0353 8.432381 6 
 
 
SD009 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 72.28187 8.950813 3 
100.000 87.40711 2.744339 2 
50.000 93.10488 1.459755 2 
25.000 120.6854 9.75119 2 
12.500 130.0578 0.7006989 2 
0.000 99.97249 11.29295 6 
 
 
SD010 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 63.77424 7.037109 3 
100.000 87.51323 14.02386 3 
50.000 81.19928 6.930481 3 
25.000 95.2028 10.1114 3 
12.500 104.2681 9.629234 3 
0.000 100.0353 8.432381 6 
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SD011 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 122.4745 5.651497 3 
100.000 119.1827 13.73535 3 
50.000 134.0522 10.78079 3 
25.000 140.4843 7.137756 3 
12.500 149.4892 16.44527 3 
0.000 99.97729 17.16466 5 
 
 
SD012 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 70.0604 1.646133 3 
100.000 97.87173 3.458076 3 
50.000 100.0575 4.211311 3 
25.000 102.646 1.91835 3 
12.500 119.7584 2.92849 2 
0.000 99.98562 10.30106 6 
 
  
SD013 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 57.37705 4.758778 2 
100.000 69.28386 6.83313 2 
50.000 81.10439 3.760918 3 
25.000 98.15932 7.495224 3 
12.500 124.2019 10.18869 2 
0.000 99.98562 10.30106 6 
 
SD014 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 80.07108 3.940079 3 
100.000 94.84641 5.349411 3 
50.000 105.7883 4.880867 3 
25.000 110.0787 1.382133 3 
12.500 105.3821 3.155273 3 
0.000 99.96192 9.784386 6 
 
 
SD015 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 81.34045 1.507919 2 
100.000 89.97206 4.233871 3 
50.000 92.99316 3.000412 3 
25.000 98.12136 1.088684 3 
12.500 102.4372 2.369583 2 
0.000 99.96192 9.784386 6 
 
 
SD016 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 90.6094 0.706398 2 
100.000 86.97969 6.206963 3 
50.000 103.9627 4.494751 3 
25.000 125.9407 16.31045 3 
12.500 116.2504 8.992287 3 
0.000 100.000 12.37921 6 
 
 
SD017 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 93.05695 8.406166 2 
100.000 90.94241 5.954178 3 
50.000 98.4349 5.635582 3 
25.000 93.7729 1.272827 3 
12.500 88.14518 11.98566 3 
0.000 100.000 12.37921 6 
 
 
SD018 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 129.9175 4.960449 2 
100.000 161.0271 10.87123 3 
50.000 160.2476 3.784561 3 
25.000 171.0683 12.14384 3 
12.500 177.7167 13.28207 3 
0.000 100.000 55.05859 6 
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Table 7.2: Graphs from 24 hour MTS Assays for Lignan Compounds SD001-18. 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001. 
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Table 7.3: One-Way ANOVAs with Dunnett’s post hoc test for absolute data from 
MTS assay of Jurkat cells treated with 0-200 µM lignan compounds SD001-18 for 
24 hours. 
Table Analyzed SD001         
One-way analysis of variance           
P value 0.0240         
P value summary *         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 3.709         
R squared 0.5698         
ANOVA Table SS df MS     
Treatment (between columns) 1775 5 355.0     
Residual (within columns) 1340 14 95.72     
Total 3115 19       
 
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A 14.29 2.065 No ns 
-5.359 to 
33.94 
Column F vs Column B -5.679 
0.710
9 No ns 
-28.37 to 
17.01 
Column F vs Column C -19.14 2.766 No ns 
-38.78 to 
0.5117 
Column F vs Column D -2.285 
0.330
3 No ns 
-21.93 to 
17.36 
Column F vs Column E -6.210 
0.897
6 No ns 
-25.86 to 
13.44 
 
 
Table Analyzed  SD002         
One-way analysis of variance           
P value 0.0291         
P value summary *         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 3.713         
R squared 0.6074         
ANOVA Table SS df MS     
Treatment (between columns) 1252 5 250.4     
Residual (within columns) 809.3 12 67.44     
Total 2061 17       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A 17.57 3.025 Yes * 
0.7196 to 
34.41 
Column F vs Column B 6.533 1.125 No ns 
-10.31 to 
23.38 
Column F vs Column C -3.532 
0.526
7 No ns 
-22.99 to 
15.92 
Column F vs Column D -7.548 1.126 No ns 
-27.00 to 
11.91 
Column F vs Column E -7.895 1.177 No ns 
-27.35 to 
11.56 
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Table Analyzed SD003         
One-way analysis of variance           
P value 0.0002         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 11.16         
R squared 0.7995         
ANOVA Table SS df MS     
Treatment (between columns) 3011 5 602.2     
Residual (within columns) 755.2 14 53.94     
Total 3766 19       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A 4.380 
0.843
3 No ns 
-10.37 to 
19.13 
Column F vs Column B -2.190 
0.421
7 No ns 
-16.94 to 
12.56 
Column F vs Column C -38.37 6.399 Yes *** 
-55.40 to -
21.34 
Column F vs Column D -14.99 2.886 Yes * 
-29.74 to -
0.2385 
Column F vs Column E -13.04 2.511 No ns 
-27.79 to 
1.708 
 
      
 
Table Analyzed  SD004         
One-way analysis of variance           
P value 0.0006         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 8.445         
R squared 0.7379         
ANOVA Table SS df MS     
Treatment (between columns) 1993 5 398.6     
Residual (within columns) 708.0 15 47.20     
Total 2701 20       
             
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A 5.693 
1.17
2 No ns 
-7.988 to 
19.37 
Column F vs Column B -12.12 
2.49
4 No ns 
-25.80 to 
1.565 
Column F vs Column C -22.09 
4.54
8 Yes ** 
-35.77 to -
8.411 
Column F vs Column D -18.00 
3.70
6 Yes ** 
-31.69 to -
4.323 
Column F vs Column E -14.01 
2.88
5 Yes * 
-27.70 to -
0.3331 
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Table Analyzed  SD005         
One-way analysis of variance           
P value 0.0004         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 11.69         
R squared 0.8416         
ANOVA Table SS df MS     
Treatment (between columns) 17880 5 3577     
Residual (within columns) 3366 11 306.0     
Total 21250 16       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 0.3145 
0.022
02 No ns 
-41.70 to 
42.32 
Column F vs Column B -22.52 1.821 No ns 
-58.90 to 
13.86 
Column F vs Column C -69.64 4.876 Yes ** 
-111.7 to -
27.63 
Column F vs Column D -59.48 4.165 Yes ** 
-101.5 to -
17.47 
Column F vs Column E -82.99 5.811 Yes *** 
-125.0 to -
40.98 
 
      
 
Table Analyzed  SD006         
One-way analysis of variance           
P value 0.0002         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 10.78         
R squared 0.7938         
ANOVA Table SS df MS     
Treatment (between columns) 3319 5 663.8     
Residual (within columns) 862.1 14 61.58     
Total 4181 19       
             
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 20.09 3.620 Yes * 
4.330 to 
35.85 
Column F vs Column B -7.378 1.330 No ns 
-23.14 to 
8.381 
Column F vs Column C -25.60 4.614 Yes ** 
-41.36 to -
9.841 
Column F vs Column D -3.467 
0.624
8 No ns 
-19.23 to 
12.29 
Column F vs Column E -9.244 1.443 No ns 
-27.44 to 
8.953 
 
      
 
Table Analyzed  SD007         
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One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 89.78         
R squared 0.9698         
ANOVA Table SS df MS     
Treatment (between columns) 33450 5 6690     
Residual (within columns) 1043 14 74.52     
Total 34500 19       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 115.0 
18.8
4 Yes *** 
97.69 to 
132.4 
Column F vs Column B 45.49 
6.45
4 Yes *** 
25.47 to 
65.51 
Column F vs Column C 13.16 
2.15
5 No ns 
-4.180 to 
30.49 
Column F vs Column D 10.04 
1.64
6 No ns 
-7.291 to 
27.38 
Column F vs Column E -9.067 
1.48
5 No ns 
-26.40 to 
8.269 
 
      
 
Table Analyzed  SD008         
One-way analysis of variance           
P value 0.0003         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 9.533         
R squared 0.7606         
            
ANOVA Table SS df MS     
Treatment (between columns) 2065 5 413.0     
Residual (within columns) 649.9 15 43.32     
Total 2715 20       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 19.96 4.290 Yes ** 
6.857 to 
33.07 
Column F vs Column B 11.25 2.418 No ns 
-1.855 to 
24.36 
Column F vs Column C 5.467 1.175 No ns 
-7.640 to 
18.57 
Column F vs Column D -8.148 1.751 No ns 
-21.26 to 
4.959 
Column F vs Column E -10.62 2.281 No ns 
-23.72 to 
2.490 
 
      
 
Table Analyzed  SD009         
  90 
One-way analysis of variance           
P value 0.0003         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 13.04         
R squared 0.8557         
ANOVA Table SS df MS     
Treatment (between columns) 5354 5 1071     
Residual (within columns) 903.1 11 82.10     
Total 6258 16       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 27.69 4.322 Yes ** 
8.845 to 
46.54 
Column F vs Column B 12.57 1.698 No ns 
-9.195 to 
34.33 
Column F vs Column C 6.868 
0.928
3 No ns 
-14.89 to 
28.63 
Column F vs Column D -20.71 2.800 No ns 
-42.47 to 
1.048 
Column F vs Column E -30.09 4.067 Yes ** 
-51.85 to -
8.325 
 
      
 
Table Analyzed  SD010         
One-way analysis of variance           
P value 0.0007         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 8.116         
R squared 0.7301         
            
ANOVA Table SS df MS     
Treatment (between columns) 3609 5 721.7     
Residual (within columns) 1334 15 88.93     
Total 4943 20       
            
Dunnett's Multiple 
Comparison Test Mean Diff. q 
Significant? P < 
0.05? 
Summ
ary 
95% CI of 
diff 
Column F vs Column A 36.26 5.438 Yes *** 
17.48 to 
55.04 
Column F vs Column B 12.52 1.878 No ns 
-6.257 to 
31.30 
Column F vs Column C 18.84 2.825 Yes * 
0.05737 to 
37.61 
Column F vs Column D 4.832 
0.724
7 No ns 
-13.95 to 
23.61 
Column F vs Column E -4.233 
0.634
8 No ns 
-23.01 to 
14.55 
 
      
 
Table Analyzed  SD011         
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One-way analysis of variance           
P value 0.0021         
P value summary **         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 6.751         
R squared 0.7068         
ANOVA Table SS df MS     
Treatment (between columns) 6015 5 1203     
Residual (within columns) 2495 14 178.2     
Total 8510 19       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A -22.50 
2.30
8 No ns 
-50.19 to 
5.191 
Column F vs Column B -19.21 
1.97
0 No ns 
-46.89 to 
8.483 
Column F vs Column C -34.07 
3.49
5 Yes * 
-61.76 to -
6.386 
Column F vs Column D -40.51 
4.15
5 Yes ** 
-68.20 to -
12.82 
Column F vs Column E -49.51 
5.07
9 Yes *** 
-77.20 to -
21.82 
 
      
 
Table Analyzed  SD012         
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 15.51         
R squared 0.8471         
            
ANOVA Table SS df MS     
Treatment (between columns) 3386 5 677.2     
Residual (within columns) 611.3 14 43.66     
Total 3997 19       
            
Dunnett's Multiple 
Comparison Test Mean Diff. q 
Significant? P < 
0.05? 
Summ
ary 
95% CI of 
diff 
Column F vs Column A 29.93 6.405 Yes *** 
16.65 to 
43.20 
Column F vs Column B 2.114 
0.452
4 No ns 
-11.16 to 
15.38 
Column F vs Column C -0.07190 
0.015
39 No ns 
-13.34 to 
13.20 
Column F vs Column D -2.660 
0.569
4 No ns 
-15.93 to 
10.61 
Column F vs Column E -19.77 3.665 Yes * 
-35.10 to -
4.450 
 
      
 
Table Analyzed  SD013         
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One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 18.02         
R squared 0.8825         
ANOVA Table SS df MS     
Treatment (between columns) 6341 5 1268     
Residual (within columns) 844.4 12 70.36     
Total 7185 17       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 42.61 6.221 Yes *** 
22.74 to 
62.48 
Column F vs Column B 30.70 4.483 Yes ** 
10.83 to 
50.57 
Column F vs Column C 18.88 3.183 Yes * 
1.673 to 
36.09 
Column F vs Column D 1.826 
0.307
9 No ns 
-15.38 to 
19.04 
Column F vs Column E -24.22 3.536 Yes * 
-44.09 to -
4.345 
 
      
 
Table Analyzed  SD014         
One-way analysis of variance           
P value 0.0006         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 8.256         
R squared 0.7335         
            
ANOVA Table SS df MS     
Treatment (between columns) 1757 5 351.4     
Residual (within columns) 638.3 15 42.56     
Total 2395 20       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 19.89 4.312 Yes ** 
6.900 to 
32.88 
Column F vs Column B 5.116 1.109 No ns 
-7.875 to 
18.11 
Column F vs Column C -5.826 1.263 No ns 
-18.82 to 
7.164 
Column F vs Column D -10.12 2.193 No ns 
-23.11 to 
2.874 
Column F vs Column E -5.420 1.175 No ns 
-18.41 to 
7.570 
 
      
 
Table Analyzed  SD015         
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One-way analysis of variance           
P value 0.0296         
P value summary *         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 3.578         
R squared 0.5792         
ANOVA Table SS df MS     
Treatment (between columns) 747.0 5 149.4     
Residual (within columns) 542.8 13 41.75     
Total 1290 18       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 18.62 3.530 Yes * 
3.490 to 
33.75 
Column F vs Column B 9.990 2.186 No ns 
-3.115 to 
23.09 
Column F vs Column C 6.969 1.525 No ns 
-6.136 to 
20.07 
Column F vs Column D 1.841 
0.402
8 No ns 
-11.26 to 
14.95 
Column F vs Column E -2.475 
0.469
2 No ns 
-17.61 to 
12.66 
 
      
 
Table Analyzed  SD016         
One-way analysis of variance           
P value 0.0045         
P value summary **         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 5.710         
R squared 0.6710         
            
ANOVA Table SS df MS     
Treatment (between columns) 3218 5 643.6     
Residual (within columns) 1578 14 112.7     
Total 4796 19       
  
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 9.391 1.083 No ns 
-15.23 to 
34.01 
Column F vs Column B 13.02 1.734 No ns 
-8.300 to 
34.34 
Column F vs Column C -3.963 
0.527
9 No ns 
-25.28 to 
17.36 
Column F vs Column D -25.94 3.456 Yes * 
-47.26 to -
4.620 
Column F vs Column E -16.25 2.165 No ns 
-37.57 to 
5.070 
 
Table Analyzed  SD017         
One-way analysis of variance           
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P value 0.5309         
P value summary ns         
Are means signif. different? (P < 
0.05) No         
Number of groups 6         
F 0.8606         
R squared 0.2351         
ANOVA Table SS df MS     
Treatment (between columns) 387.8 5 77.56     
Residual (within columns) 1262 14 90.13     
Total 1650 19       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 6.943 
0.895
7 No ns 
-15.07 to 
28.96 
Column F vs Column B 9.058 1.349 No ns 
-10.01 to 
28.12 
Column F vs Column C 1.565 
0.233
1 No ns 
-17.50 to 
20.63 
Column F vs Column D 6.227 
0.927
6 No ns 
-12.84 to 
25.29 
Column F vs Column E 11.85 1.766 No ns 
-7.211 to 
30.92 
 
 
Table Analyzed  SD018         
One-way analysis of variance           
P value 0.0337         
P value summary *         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 3.354         
R squared 0.5450         
ANOVA Table SS df MS     
Treatment (between columns) 19280 5 3856     
Residual (within columns) 16090 14 1150     
Total 35370 19       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Column F vs Column A -29.92 
1.08
1 No ns 
-108.5 to 
48.71 
Column F vs Column B -61.03 
2.54
5 No ns 
-129.1 to 
7.065 
Column F vs Column C -60.25 
2.51
3 No ns 
-128.3 to 
7.844 
Column F vs Column D -71.07 
2.96
4 Yes * 
-139.2 to -
2.976 
Column F vs Column E -77.72 
3.24
2 Yes * 
-145.8 to -
9.625 
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Table 7.4: Absolute data from MTS assay of Jurkat cells treated with 0-200 µM 
lignan compounds SD001-18 for 48 hours. 
SD001 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 76.94346 3.174072 3 
100.000 116.0483 9.617363 3 
50.000 116.9317 8.939445 3 
25.000 121.5842 1.789452 3 
12.500 106.861 5.209267 3 
0.000 99.98528 8.936577 6 
 
SD002 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 49.11661 9.369785 2 
100.000 92.2556 9.589722 3 
50.000 103.7691 0.8015671 3 
25.000 102.2968 6.028465 3 
12.500 107.9211 8.751526 3 
0.000 99.98528 8.936577 6 
 
 
SD003 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 66.41064 5.778442 3 
100.000 95.72453 6.189507 3 
50.000 94.06042 6.216141 3 
25.000 94.44445 0.4229965 3 
12.500 99.64158 3.314499 3 
0.000 100.000 8.618073 5 
 
 
SD004 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 63.28725 6.116974 3 
100.000 85.43267 15.49868 3 
50.000 84.71581 2.580688 3 
25.000 93.54839 4.856972 3 
12.500 96.56938 9.042885 3 
0.000 100.000 8.618073 5 
 
 
SD005 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 60.54422 2.287659 3 
100.000 82.80274 4.575302 3 
50.000 94.06802 4.284241 3 
25.000 92.62585 3.518105 3 
12.500 96.57143 9.065636 3 
0.000 60.54422 2.287659 3 
 
 
SD006 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 37.68708 12.72064 3 
100.000 87.34694 11.10565 3 
50.000 107.1293 21.01725 3 
25.000 97.25171 5.769028 3 
12.500 97.68709 3.53418 3 
0.000 100.0408 17.41274 6 
 
 
SD007 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 -7.574363 1.380966 3 
100.000 64.09076 1.583656 3 
50.000 92.4563 10.65093 3 
25.000 115.3327 7.343781 3 
12.500 120.0552 15.06635 3 
0.000 100.0153 7.423683 6 
 
 
SD008 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 59.12297 10.29633 3 
100.000 52.00859 7.736633 3 
50.000 68.4146 10.13853 3 
25.000 98.37474 6.769287 3 
12.500 108.7703 6.573929 3 
0.000 100.0153 7.423683 6 
 
 
SD010 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 70.14323 0.3165131 2 
100.000 71.82929 6.000435 3 
50.000 86.69053 7.173958 3 
25.000 106.3563 7.841026 3 
12.500 95.85197 6.839386 3 
0.000 100.000 6.034309 6 
 
 
SD011 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 57.37492 0.245285 3 
100.000 105.1657 11.20348 3 
50.000 108.0897 7.386215 3 
25.000 107.050 2.583008 3 
12.500 101.5919 4.964378 3 
0.000 99.98376 15.6543 6 
 
 
 
SD012 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 74.48522 4.684509 2 
100.000 68.27811 7.614059 3 
50.000 86.60101 1.793488 3 
25.000 99.07488 1.809074 3 
12.500 98.98537 7.108887 3 
0.000 100.000 6.034309 6 
 
 
 
SD013 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 72.41714 5.099998 2 
100.000 65.65952 8.289368 3 
50.000 85.60754 1.95256 3 
25.000 99.18777 1.969543 3 
12.500 99.09032 7.739403 3 
0.000 99.98376 15.6543 6 
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SD014 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 46.80232 5.657627 3 
100.000 83.78552 2.167465 3 
50.000 101.938 4.609604 3 
25.000 114.6318 17.51064 3 
12.500 98.90181 8.790276 3 
0.000 100.000 15.4689 4 
 
SD015 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 80.52325 5.024765 3 
100.000 96.83461 15.85726 3 
50.000 102.2287 5.324173 3 
25.000 116.1822 19.76269 3 
12.500 109.3346 8.736702 3 
0.000 100.000 15.4689 4 
 
 
SD016 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 61.74535 6.677834 3 
100.000 82.94707 2.400879 3 
50.000 93.93419 6.587303 3 
25.000 95.16451 7.625648 3 
12.500 101.8598 7.960793 3 
0.000 100.0286 9.837318 6 
 
 
SD017 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 70.15737 6.942886 3 
100.000 95.42204 11.81695 3 
50.000 98.28326 5.979088 3 
25.000 97.45351 5.286003 3 
12.500 95.99429 3.840019 3 
0.000 100.0286 9.837318 6 
 
 
SD018 
(uM) 
Metabolic Activity (%) 
Mean    Standard Deviation    n 
200.000 73.42902 3.403976 3 
100.000 79.52153 6.144547 3 
50.000 104.2105 14.10014 3 
25.000 101.1483 4.306221 3 
12.500 91.96171 3.729599 3 
0.000 100.000 17.70909 6 
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Table 7.5: Graphs from 48-hour MTS Assays for Lignan Compounds SD001-18. 
Data is represented as mean ± SEM. Statistical analysis was performed using the one-
way ANOVA, with Dunnett’s post-hoc test used to compare samples with the untreated 
control. * represents a p value < 0.05, ** represents a p value < 0.01, *** represents a p 
value < 0.001. 
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Table 7.6: One-Way ANOVAs with Dunnett’s post hoc test for absolute data from 
MTS assay of Jurkat cells treated with 0-200 µM lignan compounds SD001-18 for 
48 hours. 
Table Analyzed  SD001         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 15.04         
R squared 0.8337         
ANOVA Table SS 
 
df MS     
Treatment (between columns) 4136 5 827.3     
Residual (within columns) 825.0 15 55.00     
Total 4961 20       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 95% CI of diff 
Column F vs Column A 23.04 
4.39
4 Yes ** 
8.274 to 
37.81 
Column F vs Column B -16.06 
3.06
3 Yes * 
-30.83 to -
1.295 
Column F vs Column C -16.95 
3.23
2 Yes * 
-31.71 to -
2.179 
Column F vs Column D -21.60 
4.11
9 Yes ** 
-36.37 to -
6.831 
Column F vs Column E -6.876 
1.31
1 No ns 
-21.64 to 
 7.892 
      
 
Table Analyzed SD003         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 13.10         
R squared 0.8239         
ANOVA Table SS df MS     
Treatment (between columns) 2526 5 505.2     
Residual (within columns) 540.1 14 38.58     
Total 3066 19       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 33.59 7.405 Yes *** 
20.71 to 
46.47 
Column F vs Column B 4.275 0.9426 No ns 
-8.607 to 
17.16 
Column F vs Column C 5.940 1.309 No ns 
-6.943 to 
18.82 
Column F vs Column D 5.556 1.225 No ns 
-7.327 to 
18.44 
Column F vs Column E 0.3584 
0.0790
2 No ns 
-12.52 to 
13.24 
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Table Analyzed SD004         
            
One-way analysis of 
variance           
P value 0.0012         
P value summary **         
Are means signif. different? 
(P < 0.05) Yes         
Number of groups 6         
F 7.573         
R squared 0.7301         
            
ANOVA Table SS df MS     
Treatment (between 
columns) 2911 5 582.3     
Residual (within columns) 1076 14 76.88     
Total 3988 19       
            
Dunnett's Multiple 
Comparison Test Mean Diff. q 
Significant? P 
< 0.05? 
Summ
ary 
95% CI of 
diff 
Column F vs Column A 36.71 5.733 Yes *** 
18.53 to 
54.90 
Column F vs Column B 14.57 2.275 No ns 
-3.619 to 
32.75 
Column F vs Column C 15.28 2.387 No ns 
-2.902 to 
33.47 
Column F vs Column D 6.452 1.008 No ns 
-11.74 to 
24.64 
Column F vs Column E 3.431 0.5357 No ns 
-14.76 to 
21.62 
 
Table Analyzed  SD006         
            
One-way analysis of variance           
P value 0.0003         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 9.847         
R squared 0.7665         
ANOVA Table SS df MS     
Treatment (between columns) 10050 5 2010     
Residual (within columns) 3061 15 204.1     
Total 13110 20       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 62.35 6.173 Yes *** 
33.91 to 
90.80 
Column F vs Column B 12.69 1.257 No ns 
-15.75 to 
41.14 
Column F vs Column C -7.088 
0.701
7 No ns 
-35.54 to 
21.36 
Column F vs Column D 2.789 
0.276
1 No ns 
-25.66 to 
31.24 
Column F vs Column E 2.354 
0.233
0 No ns 
-26.09 to 
30.80 
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Table Analyzed SD007         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 97.68         
R squared 0.9702         
            
ANOVA Table SS 
 
df MS     
Treatment (between columns) 34940 5 6988     
Residual (within columns) 1073 15 71.54     
Total 36010 20       
Dunnett's Multiple 
Comparison Test Mean Diff. q 
Significant? P < 
0.05? 
Summ
ary 
95% CI of 
diff 
Column F vs Column A 107.6 17.99 Yes *** 
90.75 to 
124.4 
Column F vs Column B 35.92 6.007 Yes *** 
19.08 to 
52.77 
Column F vs Column C 7.559 1.264 No ns 
-9.284 to 
24.40 
Column F vs Column D -15.32 2.561 No ns 
-32.16 to 
1.526 
Column F vs Column E -20.04 3.351 Yes * 
-36.88 to -
3.197 
      
 
Table Analyzed SD008         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 29.23         
R squared 0.9069         
ANOVA Table SS 
 
df MS     
Treatment (between columns) 9655 5 1931     
Residual (within columns) 991.0 15 66.06     
Total 10650 20       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 40.89 7.115 Yes *** 
24.71 to 
57.08 
Column F vs Column B 48.01 8.353 Yes *** 
31.82 to 
64.19 
Column F vs Column C 31.60 5.498 Yes *** 
15.42 to 
47.79 
Column F vs Column D 1.641 
0.285
5 No ns 
-14.55 to 
17.83 
Column F vs Column E -8.755 1.523 No ns 
-24.94 to 
7.431 
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Table Analyzed SD010         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 16.07         
R squared 0.8516         
ANOVA Table SS df MS     
Treatment (between columns) 3292 5 658.4     
Residual (within columns) 573.6 14 40.97     
Total 3866 19       
            
Dunnett's Multiple 
Comparison Test Mean Diff. q 
Significant? P < 
0.05? 
Summ
ary 
95% CI of 
diff 
Column F vs Column A 29.86 5.713 Yes *** 
15.01 to 
44.70 
Column F vs Column B 28.17 6.224 Yes *** 
15.32 to 
41.03 
Column F vs Column C 13.31 2.941 Yes * 
0.4546 to 
26.16 
Column F vs Column D -6.356 1.404 No ns 
-19.21 to 
6.499 
Column F vs Column E 4.148 
0.916
4 No ns 
-8.707 to 
17.00 
      
 
 
 
Table Analyzed SD011         
            
One-way analysis of variance           
P value 0.0002         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 10.37         
R squared 0.7757         
ANOVA Table SS df MS     
Treatment (between columns) 5699 5 1140     
Residual (within columns) 1648 15 109.9     
Total 7347 20       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Column F vs Column A 42.61 5.749 Yes *** 
21.73 to 
63.48 
Column F vs Column B -5.182 
0.699
1 No ns 
-26.06 to 
15.69 
Column F vs Column C -8.106 1.094 No ns 
-28.98 to 
12.77 
Column F vs Column D -7.066 
0.953
3 No ns 
-27.94 to 
13.81 
Column F vs Column E -1.608 
0.217
0 No ns 
-22.48 to 
19.27 
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Table Analyzed  SD012         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 19.47         
R squared 0.8743         
ANOVA Table SS df MS     
Treatment (between columns) 3018 5 603.6     
Residual (within columns) 434.0 14 31.00     
Total 3452 19       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Column F vs Column A 25.51 5.612 Yes *** 
12.60 to 
38.43 
Column F vs Column B 31.72 8.057 Yes *** 
20.54 to 
42.90 
Column F vs Column C 13.40 3.403 Yes * 
2.217 to 
24.58 
Column F vs Column D 0.9251 
0.235
0 No ns 
-10.26 to 
12.11 
Column F vs Column E 1.015 
0.257
7 No ns 
-10.17 to 
12.20 
      
 
Table Analyzed SD014         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 13.89         
R squared 0.8424         
ANOVA Table SS df MS     
Treatment (between columns) 8558 5 1712     
Residual (within columns) 1602 13 123.2     
Total 10160 18       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 53.20 6.275 Yes *** 
28.88 to 
77.51 
Column F vs Column B 16.21 1.913 No ns 
-8.099 to 
40.53 
Column F vs Column C -1.938 
0.228
6 No ns 
-26.25 to 
22.38 
Column F vs Column D -14.63 1.726 No ns 
-38.95 to 
9.682 
Column F vs Column E 1.098 
0.129
5 No ns 
-23.22 to 
25.41 
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Table Analyzed SD015         
            
One-way analysis of variance           
P value 0.0808         
P value summary ns         
Are means signif. different? (P 
< 0.05) No         
Number of groups 6         
F 2.549         
R squared 0.4951         
ANOVA Table SS df MS     
Treatment (between columns) 2218 5 443.5     
Residual (within columns) 2262 13 174.0     
Total 4479 18       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 19.48 1.933 No ns 
-9.417 to 
48.37 
Column F vs Column B 3.165 
0.314
2 No ns 
-25.73 to 
32.06 
Column F vs Column C -2.229 
0.221
2 No ns 
-31.12 to 
26.66 
Column F vs Column D -16.18 1.606 No ns 
-45.08 to 
12.71 
Column F vs Column E -9.335 
0.926
6 No ns 
-38.23 to 
19.56 
 
      
 
Table Analyzed SD016         
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 12.08         
R squared 0.8011         
ANOVA Table SS df MS     
Treatment (between columns) 3682 5 736.4     
Residual (within columns) 914.4 15 60.96     
Total 4597 20       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 38.28 6.934 Yes *** 
22.74 to 
53.83 
Column F vs Column B 17.08 3.094 Yes * 
1.534 to 
32.63 
Column F vs Column C 6.094 1.104 No ns 
-9.454 to 
21.64 
Column F vs Column D 4.864 
0.881
0 No ns 
-10.68 to 
20.41 
Column F vs Column E -1.831 
0.331
7 No ns 
-17.38 to 
13.72 
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Table Analyzed SD017         
            
One-way analysis of variance           
P value 0.0031         
P value summary **         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 6         
F 5.998         
R squared 0.6666         
ANOVA Table SS df MS     
Treatment (between columns) 2032 5 406.4     
Residual (within columns) 1016 15 67.76     
Total 3049 20       
            
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 29.87 5.132 Yes *** 
13.48 to 
46.26 
Column F vs Column B 4.607 
0.791
4 No ns 
-11.79 to 
21.00 
Column F vs Column C 1.745 
0.299
9 No ns 
-14.65 to 
18.14 
Column F vs Column D 2.575 
0.442
4 No ns 
-13.82 to 
18.97 
Column F vs Column E 4.034 
0.693
1 No ns 
-12.36 to 
20.43 
 
Table Analyzed SD018         
            
One-way analysis of variance           
P value 0.0240         
P value summary *         
Are means signif. different? (P 
< 0.05) Yes         
Number of groups 6         
F 3.617         
R squared 0.5466         
            
ANOVA Table SS df MS     
Treatment (between columns) 2567 5 513.5     
Residual (within columns) 2129 15 142.0     
Total 4697 20       
Dunnett's Multiple Comparison 
Test Mean Diff. q 
Significant? P < 
0.05? 
Summa
ry 
95% CI of 
diff 
Column F vs Column A 26.57 3.154 Yes * 
2.845 to 
50.30 
Column F vs Column B 20.48 2.431 No ns 
-3.247 to 
44.20 
Column F vs Column C -4.211 
0.499
8 No ns 
-27.94 to 
19.52 
Column F vs Column D -1.148 
0.136
3 No ns 
-24.87 to 
22.58 
Column F vs Column E 8.038 
0.954
1 No ns 
-15.69 to 
31.76 
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Table 7.7: Absolute data for Annexin V/PI analysis of Jurkat cells treated for 24 hours with 0-200 µM of lignan compounds 
SD001-18.  
 
Lignan Concentration 
(µM) Viable Early Apoptotic Late Apoptotic Necrotic 
SD001 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 73.38333 3.792049 3 18.44667 2.646136 3 7.096667 1.710624 3 1.073333 0.5205126 3 
100 83.43667 6.353742 3 8.16 2.65684 3 6.593333 3.819232 3 1.81 0.362905 3 
50 86.40333 0.9392726 3 6.193333 0.3150133 3 5.266667 0.3312601 3 2.136667 0.6909655 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD002 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 68.27334 2.410236 3 22.47 1.516541 3 8.47 1.358418 3 0.7866666 0.2702468 3 
100 85.57999 1.694342 3 6.78 0.3874274 3 5.84 1.353477 3 1.8 0.506853 3 
50 84.83666 2.984698 3 5.853333 1.356515 3 6.113333 1.622848 3 3.196667 1.117915 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD003 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 74.14667 2.231601 3 17.66667 1.985682 3 6.693333 0.4072263 3 1.493333 0.3827967 3 
100 80.93 1.922418 3 11.56 1.138727 3 6.256667 0.3003888 3 1.253333 0.4895236 3 
50 83.85667 0.4992336 3 9.463333 0.2458323 3 5.133333 0.3362044 3 1.546667 0.5089532 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD004 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 68.13667 3.988203 3 16.99 2.447183 3 13.8 2.099309 3 1.073333 0.627402 3 
100 78.22334 2.633484 3 9.526668 0.5953429 3 11.48333 2.301311 3 0.7666667 0.3837099 3 
50 76.00333 1.696622 3 9.75 1.305641 3 13.18333 1.956459 3 1.063333 1.342473 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD005 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 64.29333 3.762213 3 17.81 4.981335 3 11.16333 3.609326 3 6.733334 4.64696 3 
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100 83.64333 4.685105 3 6.736666 1.906471 3 4.476667 0.8800758 3 5.143333 2.027248 3 
50 82.38667 2.16853 3 6.533333 1.277863 3 5.356667 1.860573 3 5.723333 4.117734 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD006 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 72.53333 1.459361 3 12.69667 1.182638 3 13.22 0.2685148 3 1.55 0.5086256 3 
100 79.19 1.105305 3 8.146667 0.6226825 3 10.88 0.2306515 3 1.783333 0.3231615 3 
50 78.80334 2.345045 3 8.150001 0.6165225 3 11.19333 1.500011 3 1.853333 0.6027714 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD007 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 5.8 2.041176 7 26.91333 5.79126 9 62.78778 12.95376 9 1.178889 1.720991 9 
100 72.35222 2.745499 9 10.04111 0.9930062 9 14.02222 3.708699 9 3.584444 3.967664 9 
50 75.90111 3.697271 9 10.64222 3.461274 9 10.58222 4.595783 9 3.232222 3.672488 9 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD008 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 49.79667 5.208803 6 28.45 3.685567 6 20.645 1.66583 6 1.108333 0.9087666 6 
100 73.90833 4.535635 6 11.83 2.161657 6 12.905 2.234697 6 1.356667 0.9609092 6 
50 73.865 7.82549 6 11.96667 3.21561 6 12.45333 3.410922 6 1.715 1.484503 6 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD009 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 46.52 8.027529 6 35.15333 7.588181 6 17.67333 1.09469 6 0.6533334 0.5246586 6 
100 72.64167 3.654972 6 13.17833 2.169843 6 12.78667 1.478738 6 1.393333 1.03857 6 
50 72.83833 5.03945 6 13.15333 2.738275 6 12.46833 1.612469 6 1.54 1.058603 6 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD010 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 46.28222 23.25723 9 24.83 11.82619 9 27.93111 11.19931 9 0.9566666 0.5727565 9 
100 62.07889 17.7979 9 17.01 7.480533 9 19.59222 9.902913 9 1.318889 0.7513229 9 
50 70.65667 6.15797 9 14.37667 3.563208 9 13.49556 3.421649 9 1.47 1.263576 9 
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0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD011 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 76.31 0.806164 3 12.16333 0.2173322 3 10.59667 0.8470145 3 0.93 0.23 3 
100 76.19666 0.5021289 3 11.67667 0.3787259 3 9.673333 0.1011601 3 2.453333 0.4359281 3 
50 75.82667 1.529585 3 10.64667 0.4119869 3 10.52333 1.092261 3 3.003333 0.458294 3 
0 79.11445 6.406799 18 7.427778 1.728895 18 10.92222 5.280658 18 2.535556 2.203968 18 
SD012 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 35.90333 2.742414 3 13.67 1.70845 3 49.04667 1.570552 3 1.38 0.7211103 3 
100 65.66334 2.952495 3 8.133333 0.6074814 3 24.09333 1.783041 3 2.11 0.5726256 3 
50 72.61333 1.369538 3 7.146667 0.4536887 3 18.95667 1.255242 3 1.283333 0.1778576 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD013 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 34.42667 1.211295 3 16.37 0.2511974 3 44.19333 0.8500775 3 5.01 0.3143246 3 
100 41.20333 2.815286 3 15.60667 0.9392726 3 40.67667 0.7392116 3 2.513333 1.68693 3 
50 74.88 2.013429 3 11.72333 1.519517 3 12.78333 0.3622615 3 0.6133333 0.136504 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD014 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 55.04 2.934552 3 7.28 0.2718456 3 34.65667 3.320426 3 3.023333 1.098651 3 
100 72.32999 1.203787 3 11.5 1.300461 3 14.64333 0.1887683 3 1.526667 0.340196 3 
50 75.92333 4.584337 3 12.41667 0.6900966 3 10.45667 3.308812 3 1.203333 0.6607824 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD015 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 75.96 1.67699 3 8.7 0.6295236 3 14.58333 1.341243 3 0.7566667 0.211266 3 
100 76.42333 1.535752 3 12.15333 0.9667127 3 10.59333 0.7484872 3 0.83 0.2523886 3 
50 79.78333 2.371691 3 11.31667 1.297318 3 8.36 1.040577 3 0.54 0.1374773 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD016 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
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200 67.20667 1.151532 3 13.52333 0.7240396 3 17.91333 1.224595 3 1.356667 0.4476978 3 
100 69.87 2.743375 3 18.65667 2.587128 3 10 1.213095 3 1.473333 0.4697162 3 
50 74.88 1.729886 3 17.21333 1.819954 3 7.043334 0.4100405 3 0.8633333 0.4554485 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD017 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 84.53666 2.105049 3 8.473333 0.9700685 3 6.336667 0.9411873 3 0.6533333 0.2773686 3 
100 83.66333 3.324222 3 7.91 0.8601745 3 7.28 2.098666 3 1.146667 0.3693689 3 
50 87.48334 2.094047 3 5.4 0.1915726 3 6.003334 1.521326 3 1.113333 0.6035175 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
SD018 Mean S.D. n Mean S.D. n Mean S.D. n Mean S.D. n 
200 37.40333 1.713164 3 19.73667 0.5231001 3 40.46333 0.6724831 3 2.396667 0.6789208 3 
100 47.15 2.990535 3 18.16667 0.4473628 3 32.94667 1.903927 3 1.736667 0.6782576 3 
50 67.79 5.430689 3 23.26 5.420212 3 8.523334 0.1365042 3 0.4266666 0.1527525 3 
0 85.54 2.984364 9 5.208889 0.6466538 9 8.147778 2.224583 9 1.103333 0.3783186 9 
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Table 7.8: Cell cycle analysis for Jurkat cells in G1-phase following 4 hours incubation with 100 µM lignan compounds SD001-
18 and camptothecin. 
 
 Control SD001 SD002 SD003 SD004 SD006 SD007 SD008 SD010 SD011 SD012 SD013 SD014 SD015 SD016 SD017 SD018 
Pos. 
Control 
Number of 
values 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Minimum 64.51 65.81 64.83 64.98 64.68 64.76 65.31 66.21 66.16 65.67 67.13 66.65 66.51 65.71 65.73 66.16 65.77 76.4 
25% 
Percentile 64.51 65.81 64.83 64.98 64.68 64.76 65.31 66.21 66.16 65.67 67.13 66.65 66.51 65.71 65.73 66.16 65.77 76.4 
Median 65.96 65.93 65.23 65.3 65.52 65.31 67.04 67.1 66.78 66.29 67.24 67.22 66.54 66.63 66.15 66.84 66.25 76.85 
75% 
Percentile 67.29 66.65 65.9 66.53 66.75 67.39 67.94 67.99 67.87 67.31 67.96 67.35 66.95 66.75 68.86 67.47 69.61 79.06 
Maximum 67.29 66.65 65.9 66.53 66.75 67.39 67.94 67.99 67.87 67.31 67.96 67.35 66.95 66.75 68.86 67.47 69.61 79.06 
Mean 65.92 66.13 65.32 65.6 65.65 65.82 66.76 67.1 66.94 66.42 67.44 67.07 66.67 66.36 66.91 66.82 67.21 77.44 
Std. 
Deviation 1.39 0.4543 0.5406 0.8183 1.041 1.387 1.337 0.89 0.8657 0.8281 0.4508 0.3723 0.2458 0.569 1.699 0.6552 2.092 1.424 
Std. Error 0.8028 0.2623 0.3121 0.4725 0.6011 0.8009 0.7717 0.5138 0.4998 0.4781 0.2603 0.215 0.1419 0.3285 0.9809 0.3783 1.208 0.822 
Lower 95% 
CI of mean 62.47 65 63.98 63.57 63.06 62.37 63.44 64.89 64.79 64.37 66.32 66.15 66.06 64.95 62.69 65.2 62.01 73.9 
Upper 95% 
CI of mean 69.37 67.26 66.66 67.64 68.24 69.27 70.08 69.31 69.09 68.48 68.56 68 67.28 67.78 71.13 68.45 72.41 80.97 
Sum 197.8 198.4 196 196.8 197 197.5 200.3 201.3 200.8 199.3 202.3 201.2 200 199.1 200.7 200.5 201.6 232.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  112 
Table 7.9: Cell cycle analysis for Jurkat cells in S-phase following 4 hours incubation with 100 µM lignan compounds SD001-
18 and camptothecin. 
 
 Control SD001 SD002 SD003 SD004 SD006 SD007 SD008 SD010 SD011 SD012 SD013 SD014 SD015 SD016 SD017 SD018 Pos. Control 
Number of values 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Minimum 23.64 24.05 24.6 24.04 24.19 23.52 24.74 25.69 25.81 24.3 25.4 25.39 25.81 25.96 24.58 22.01 24.21 16.59 
25% Percentile 23.64 24.05 24.6 24.04 24.19 23.52 24.74 25.69 25.81 24.3 25.4 25.39 25.81 25.96 24.58 22.01 24.21 16.59 
Median 24.17 24.54 25.63 25.16 25.36 25.03 25.33 26.54 26.72 25.13 25.79 26.32 25.84 26.7 27.86 24.7 26.55 17.4 
75% Percentile 25.6 24.56 26.2 25.85 25.53 26.23 26.83 26.67 26.82 25.68 26.11 26.56 26.54 26.85 27.97 25.5 27.6 18.32 
Maximum 25.6 24.56 26.2 25.85 25.53 26.23 26.83 26.67 26.82 25.68 26.11 26.56 26.54 26.85 27.97 25.5 27.6 18.32 
Mean 24.47 24.38 25.48 25.02 25.03 24.93 25.63 26.3 26.45 25.04 25.77 26.09 26.06 26.5 26.8 24.07 26.12 17.44 
Std. Deviation 1.014 0.2888 0.8109 0.9135 0.7295 1.358 1.078 0.5323 0.5565 0.6947 0.3556 0.618 0.4131 0.4765 1.926 1.828 1.735 0.8656 
Std. Error 0.5853 0.1668 0.4682 0.5274 0.4212 0.784 0.6221 0.3073 0.3213 0.4011 0.2053 0.3568 0.2385 0.2751 1.112 1.056 1.002 0.4997 
Lower 95% CI of 
mean 21.95 23.67 23.46 22.75 23.21 21.55 22.96 24.98 25.07 23.31 24.88 24.55 25.04 25.32 22.02 19.53 21.81 15.29 
Upper 95% CI of 
mean 26.99 25.1 27.49 27.29 26.84 28.3 28.31 27.62 27.83 26.76 26.65 27.63 27.09 27.69 31.59 28.61 30.43 19.59 
Sum 73.41 73.15 76.43 75.05 75.08 74.78 76.9 78.9 79.35 75.11 77.3 78.27 78.19 79.51 80.41 72.21 78.36 52.31 
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Table 7.10: Cell cycle analysis for Jurkat cells in G2-phase following 4 hours incubation with 100 µM lignan compounds 
SD001-18 and camptothecin (positive control). 
 
 Control SD001 SD002 SD003 SD004 SD006 SD007 SD008 SD010 SD011 SD012 SD013 SD014 SD015 SD016 SD017 SD018 Pos. Control 
Number of values 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 
Minimum 9.09 9.3 8.57 9.18 8.95 9 7.32 6.23 6.32 8.39 6.64 6.47 6.92 6.55 6 8.34 6.15 4.34 
25% Percentile 9.09 9.3 8.57 9.18 8.95 9 7.32 6.23 6.32 8.39 6.64 6.47 6.92 6.55 6 8.34 6.15 4.34 
Median 9.87 9.5 9.5 9.44 9.11 9.09 7.63 6.32 6.5 8.58 6.65 6.78 7.24 7.41 6.3 8.46 6.18 5.28 
75% Percentile 9.89 9.64 9.54 9.54 9.95 9.66 7.86 7.24 7.02 8.64 7.09 7.27 7.65 7.43 6.56 10.52 7.69 5.75 
Maximum 9.89 9.64 9.54 9.54 9.95 9.66 7.86 7.24 7.02 8.64 7.09 7.27 7.65 7.43 6.56 10.52 7.69 5.75 
Mean 9.617 9.48 9.203 9.387 9.337 9.25 7.603 6.597 6.613 8.537 6.793 6.84 7.27 7.13 6.287 9.107 6.673 5.123 
Std. Deviation 0.4562 0.1709 0.5488 0.1858 0.5372 0.3579 0.271 0.559 0.3635 0.1305 0.257 0.4034 0.3659 0.5024 0.2802 1.225 0.8806 0.7179 
Std. Error 0.2634 0.09866 0.3169 0.1073 0.3101 0.2066 0.1565 0.3227 0.2099 
0.0753
5 0.1484 0.2329 0.2113 0.2901 0.1618 0.7075 0.5084 0.4145 
Lower 95% CI of 
mean 8.483 9.056 7.84 8.925 8.002 8.361 6.93 5.208 5.71 8.212 6.155 5.838 6.361 5.882 5.591 6.062 4.486 3.34 
Upper 95% CI of 
mean 10.75 9.904 10.57 9.848 10.67 10.14 8.276 7.985 7.516 8.861 7.432 7.842 8.179 8.378 6.983 12.15 8.861 6.907 
Sum 28.85 28.44 27.61 28.16 28.01 27.75 22.81 19.79 19.84 25.61 20.38 20.52 21.81 21.39 18.86 27.32 20.02 15.37 
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Table 7.11: One-Way ANOVA and Dunnet’s Post hoc test of Jurkat cells in G1-
phase following 4 hours treatment with 100 µM lignan compounds SD001-18 
and camptothecin compared to the untreated control 
 
 
 
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 18         
F 18.51         
R squared 0.8974         
            
ANOVA Table SS df MS     
Treatment (between columns) 359.7 17 21.16     
Residual (within columns) 41.14 36 1.143     
Total 400.8 53       
Dunnett's Multiple Comparison 
Test 
Mean 
Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Control vs SD001 -0.2100 0.2406 No ns 
-2.849 to 
2.429 
Control vs SD002 0.6000 0.6874 No ns 
-2.039 to 
3.239 
Control vs SD003 0.3167 0.3628 No ns 
-2.323 to 
2.956 
Control vs SD004 0.2700 0.3093 No ns 
-2.369 to 
2.909 
Control vs SD006 0.1000 0.1146 No ns 
-2.539 to 
2.739 
Control vs SD007 -0.8433 0.9662 No ns 
-3.483 to 
1.796 
Control vs SD008 -1.180 1.352 No ns 
-3.819 to 
1.459 
Control vs SD010 -1.017 1.165 No ns 
-3.656 to 
1.623 
Control vs SD011 -0.5033 0.5767 No ns 
-3.143 to 
2.136 
Control vs SD012 -1.523 1.745 No ns 
-4.163 to 
1.116 
Control vs SD013 -1.153 1.321 No ns 
-3.793 to 
1.486 
Control vs SD014 -0.7467 0.8554 No ns 
-3.386 to 
1.893 
Control vs SD015 -0.4433 0.5079 No ns 
-3.083 to 
2.196 
Control vs SD016 -0.9933 1.138 No ns 
-3.633 to 
1.646 
Control vs SD017 -0.9033 1.035 No ns 
-3.543 to 
1.736 
Control vs SD018 -1.290 1.478 No ns 
-3.929 to 
1.349 
Control vs Camptothecin -11.52 13.19 Yes *** 
-14.16 to -
8.877 
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Table 7.12: One-Way ANOVA Jurkat cells in S-phase following 4 hours 
incubation with 100 µM lignan compounds SD001-18 and camptothecin 
compared to the untreated control. 
 
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 18         
F 12.19         
R squared 0.8520         
            
ANOVA Table SS df MS     
Treatment (between columns) 218.1 17 12.83     
Residual (within columns) 37.87 36 1.052     
Total 256.0 53       
            
Dunnett's Multiple Comparison 
Test 
Mean 
Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Control vs SD001 0.08667 
0.103
5 No ns -2.446 to 2.619 
Control vs SD002 -1.007 1.202 No ns -3.539 to 1.526 
Control vs SD003 -0.5467 
0.652
8 No ns -3.079 to 1.986 
Control vs SD004 -0.5567 
0.664
7 No ns -3.089 to 1.976 
Control vs SD006 -0.4567 
0.545
3 No ns -2.989 to 2.076 
Control vs SD007 -1.163 1.389 No ns -3.696 to 1.369 
Control vs SD008 -1.830 2.185 No ns 
-4.362 to 
0.7024 
Control vs SD010 -1.980 2.364 No ns 
-4.512 to 
0.5524 
Control vs SD011 -0.5667 
0.676
6 No ns -3.099 to 1.966 
Control vs SD012 -1.297 1.548 No ns -3.829 to 1.236 
Control vs SD013 -1.620 1.934 No ns 
-4.152 to 
0.9124 
Control vs SD014 -1.593 1.903 No ns 
-4.126 to 
0.9391 
Control vs SD015 -2.033 2.428 No ns 
-4.566 to 
0.4991 
Control vs SD016 -2.333 2.786 No ns 
-4.866 to 
0.1991 
Control vs SD017 0.4000 
0.477
6 No ns -2.132 to 2.932 
Control vs SD018 -1.650 1.970 No ns 
-4.182 to 
0.8824 
Control vs Camptothecin 7.033 8.398 Yes *** 4.501 to 9.566 
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Table 7.13: One-Way ANOVA Jurkat cells in G2-phase following 4 hours 
incubation with 100 µM lignan compounds SD001-18 and camptothecin 
compared to the untreated control. 
 
Table Analyzed G2          
            
One-way analysis of variance           
P value < 0.0001         
P value summary ***         
Are means signif. different? (P < 
0.05) Yes         
Number of groups 18         
F 21.30         
R squared 0.9096         
            
ANOVA Table SS df MS     
Treatment (between columns) 100.8 17 5.929     
Residual (within columns) 10.02 36 0.2784     
Total 110.8 53       
            
Dunnett's Multiple Comparison 
Test 
Mean 
Diff. q 
Significant? P < 
0.05? 
Summar
y 95% CI of diff 
Control vs SD001 0.1367 0.3172 No ns 
-1.166 to 
1.439 
Control vs SD002 0.4133 0.9595 No ns 
-0.8894 to 
1.716 
Control vs SD003 0.2300 0.5339 No ns 
-1.073 to 
1.533 
Control vs SD004 0.2800 0.6500 No ns 
-1.023 to 
1.583 
Control vs SD006 0.3667 0.8511 No ns 
-0.9360 to 
1.669 
Control vs SD007 2.013 4.673 Yes *** 
0.7106 to 
3.316 
Control vs SD008 3.020 7.010 Yes *** 1.717 to 4.323 
Control vs SD010 3.003 6.971 Yes *** 1.701 to 4.306 
Control vs SD011 1.080 2.507 No ns 
-0.2227 to 
2.383 
Control vs SD012 2.823 6.554 Yes *** 1.521 to 4.126 
Control vs SD013 2.777 6.445 Yes *** 1.474 to 4.079 
Control vs SD014 2.347 5.447 Yes *** 1.044 to 3.649 
Control vs SD015 2.487 5.772 Yes *** 1.184 to 3.789 
Control vs SD016 3.330 7.730 Yes *** 2.027 to 4.633 
Control vs SD017 0.5100 1.184 No ns 
-0.7927 to 
1.813 
Control vs SD018 2.943 6.832 Yes *** 1.641 to 4.246 
Control vs Camptothecin 4.493 10.43 Yes *** 3.191 to 5.796 
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Figure 7.1: Western Blot images of HSPB1 levels (left) and β-actin levels (right) 
using protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
 
  
 
Figure 7.2: Western Blot images of HSPA1A levels (left) and β-actin levels (right) 
using protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
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Figure 7.3: Western Blot images of p-Akt levels and β-actin levels using protein 
extracts from Jurkat cells treated for 4 hours with 100 µM of lignan compounds 
SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated control. 
 
 
 
 
 
 
Figure 7.4: Western Blot images of Akt levels and β-actin levels using protein 
extracts from Jurkat cells treated for 4 hours with 100 µM of lignan compounds 
SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated control. 
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Figure 7.5: Western Blot images of phospo-ß-catenin levels and β-actin levels 
using protein extracts from Jurkat cells treated for 4 hours with 100 µM of lignan 
compounds SD007, SD010, SD011, SD012, SD013 and SD018, and an untreated 
control. 
 
 
